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Abstract
In this paper, we provide a mathematical model of the effect of aspirin on
blood clotting. The model tracks the enzyme prostaglandin H synthase
and an important blood clotting factor, thromboxane A2, in the form of
thromboxane B2. Through model analysis, we determine conditions under
which the reactions of prostaglandin H synthase are self-sustaining. Lastly,
through numerical simulations, we demonstrate that the the model accu-
rately captures the steady-state chemical concentrations of interest in blood,
both with and without aspirin treatment.
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Chapter 1
Introduction
Aspirin is a widely used drug known to aid in the prevention of numer-
ous conditions and diseases, such as heart attack and stroke (U.S. Food and
Drug Administration, 2014), due to its blood-thinning properties that in-
crease the amount of time taken for blood to clot. In 2005, about one in five
adults, of age 18 or older, reported taking aspirin every day or every other
day in the United States (Soni, 2007). In 2014, a sampling survey in Wash-
ington reported a statistic of about two in five adults taking aspirin every
day or every other day (Roth et al., 2014).
Information about aspirin is collected experimentally; no mathematical
model that takes into account the effect of aspirin on blood clotting exists.
Such a model could provide insight into the workings of aspirin and could
predict the effects that different doses might have on blood clotting, with-
out having to conduct experiments on human subjects in order to obtain
numbers and results.
Most mathematical models and research on blood clotting revolves a-
round modeling the blood itself. They consist of complicated, advanced
mathematics and take into account flow and shear of the blood. However,
Wei et al. conducted research on prostaglandin H synthase, an enzyme that
plays a key role in coagulation, and proposed two different mechanisms
for this enzyme: a branched chain mechanism and a tightly coupled mech-
anism (1995). Their branched chain mechanism became widely accepted
and used by other researchers. While Wei’s model focused on the chemical
mechanism of the enzyme, and not on mathematical research or results, it
offered an alternative way of looking at blood clotting, one that was quan-
tifiable and measurable, other than just the blood itself (1995). Furthermore,
understanding the chemistry and deriving chemical equations to model the
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mechanism is crucial in potentially constructing differential equations for
mathematical modeling.
Tien et al. used the branched chain mechanism from Wei et al. (1995)
to derive a simplified Michaelis-Menten-style model for the enzyme. They
then analyzed the fixed points to determine when the enzyme would be-
come self-sustaining and performed a quasi-steady-state approximation on
the model to reduce the dimensionality of the system, leaving implications
for a simpler model that might be easier to integrate into other systems
(2005).
Despite the advances made by both Wei et al. (1995) and Tien et al. (2005)
to build a mathematical model for blood clotting, neither Wei et al. nor Tien
et al. factored in the use of aspirin, a widely known preventative for blood
clotting, or tracked variables that could be used to determine the normality,
or abnormality, of blood clotting exhibited by the models. Our goal for this
project was to construct a full, but simple, model of blood clotting, simi-
lar to the one proposed by Wei et al. (1995), while adding aspirin into the
model, as well as something quantifiable to track what is considered “nor-
mal” versus “decreased” blood clotting, which was attained in Chapter 5.
We also aimed to reduce the model to perform a stability analysis, such as
Tien et al. (2005) did, which would tell us when the model would become
self-sustaining, which was done in Chapter 4. We achieved our goals and
developed a model that, with accompanying analyses, gave us insight as
to how aspirin is integrated into the mechanisms of blood clotting in a way
that prevents coagulation and could also potentially serve as a means of
accurately determining aspirin dosages that would effectively prevent un-
wanted blood clotting.
Chapter 2
Biochemical Background
We begin by providing the reader with some background information on
the biochemistry behind our project.
2.1 Blood Clotting Cascade and Inhibition
Coagulation, or blood clotting, is a complex process involving numerous
chemicals and proteins that interact in an intricate web of pathways. We
have simplified the model and present only the basic and necessary facts
that pertain to this project.
The blood clotting cascade is prompted by damage, such as a small tear,
to the lining of the blood vessel wall. Platelets, blood cells that special-
ize in blood clotting, aggregate and adhere at the site of damage and re-
lease chemical-containing granules (Dahlbäck, 2005). One such chemical
is thromboxane A2, which promotes additional platelet aggregation, thus
making it a prominent factor in the blood clotting cascade (Anand et al.,
2003).
The enzyme responsible for the production of thromboxane A2 is prosta-
glandin H synthase, or PGHS. A known mechanism of halting the blood
clotting cascade is to inhibit PGHS with cyclooxygenase inhibitor drugs,
such as aspirin. Without thromboxane A2, further platelet aggregation will
not occur, and a blood clot will not form. Because platelets cannot recover
new PGHS molecules once they are inhibited by aspirin, the effects of as-
pirin on platelets last for the duration of the platelet’s life, which is about
ten days long. Thus, a single ingestion of aspirin is not enough to promote
blood thinning or prevent an unwanted blood clot; daily use is required to
inhibit any new platelets being formed. Because of aspirin’s blood-thinning
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properties, taking a daily dose of aspirin is recommended for those with
angina or with previous heart attack or stroke history (Awtry and Loscalzo,
2000).
2.2 Enzymes
This section provides the reader with a brief overview of enzymes and how
they work that is kept in the scope of this project.
Enzymes are proteins that catalyze reactions, increasing the speed of
the reactions, and have domains, or sites, of catalysis, where the reaction
occurs. It is possible for an enzyme to have more than one catalytic domain,
as is the case with PGHS. Reactants, known as the substrates, bind to the
site of catalysis, and after the reaction takes place, the products are released.
When the reactants are bound to the enzyme, we refer to the combined
molecules as an enzyme-substrate complex. Lastly, the catalytic domains
may have their shape or chemical features altered, causing the enzyme to
exhibit different forms.
One of many ways that enzymes can be inhibited is through binding of
inhibitors to the enzyme. There are two such types of inhibitors: compet-
itive and noncompetitive. Competitive inhibitors bind to the site of catal-
ysis, thus competing with the intended substrate for the catalytic domain.
Noncompetitive inhibitors bind elsewhere on the enzyme, and as a result,
changes the shape or properties of the catalytic site, rendering the site un-
bindable for the substrate (cf. Nelson and Cox, 2012).
2.2.1 Autocatalytic Enzymes and Self-Sustaining Reactions
An autocatalytic enzyme is one in which the product of a reaction serves as
a catalyst for future reactions. Such an enzyme is said to be self-sustaining
when the reactions continue indefinitely (cf. Nelson and Cox, 2012).
2.3 Prostaglandin H Synthase
Prostaglandin H synthase, or PGHS, is the enzyme responsible for the pro-
duction of thromboxane A2, or TXA2. However, it does not directly cat-
alyze the production of TXA2; rather, it catalyzes the reactions that produce
prostaglandin H2, a precursor for TXA2 (Tien et al., 2005).
PGHS is an autocatalytic enzyme that has two catalytic sites, one of
which catalyzes a peroxidase, or POX, reaction and the other of which
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catalyzes a cyclooxygenase, or COX, reaction, that work together cooper-
atively (Seta and Bachsmid, 2012). In the POX reaction, PGHS catalyzes
the conversion of prostaglandin G2, or PGG2 to prostaglandin H2, or PGH2.
In the COX reaction, PGHS catalyzes the conversion of arachidonic acid to
PGG2. The product of the POX reaction, PGH2 is then converted into TXA2,
a reaction that is catalyzed by a different enzyme, thromboxane A synthase.
The COX function of PGHS may be lost through enzyme suicide inactiva-
tion (Seta and Bachsmid, 2012). Figure 2.1 shows a flowchart of the chain of
reactions, where the boxes denote the enzymes.
Aspirin inhibits TXA2 production by acting as a competitive inhibitor
and irreversibly binding to the COX site of PGHS (Goltsov et al., 2010).
Thus, production of PGG2, and consequently PGH2 and TXA2, is inhibited.
Figure 2.1 Chain of reactions of PGHS without aspirin.

Chapter 3
Building the Model
3.1 Justification
The construction of our model of aspirin’s effect on blood clotting began
with the branched chain mechanism proposed by Wei et al. (1995):
Fe(I I I) + PGG2
k1→ Fe(IV)PP• + PGH2
Fe(IV)PP• k2→ Fe(IV)Tyr•
Fe(IV)Tyr• + AA k3→ Fe(IV)AA•/Tyr
Fe(IV)AA•/Tyr +O2
k4→ Fe(IV)AAO2•/Tyr (3.1)
Fe(IV)AAO2•/Tyr +O2
k5→ Fe(IV)Tyr• + PGG2
Fe(IV)PP• + FA k6→ Fe(IV) + FA•
Fe(IV)Tyr• + FA k7→ FE(IV) + FA•
Fe(IV) + FA
k8→ Fe(I I I) + FA•
where Fe’s denote different forms of the enzyme PGHS and • denotes rad-
ical chemistry, AA is arachidonic acid, O2 is oxygen, and FA is ferulic acid.
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We simplified these equations, omitting the radical chemistry and sub-
strates oxygen and ferulic acid, to obtain:
E1 + P
k1→ E2 + H
E2
k2→ E3
E3 + S
k3→ C1 k4→ C2 k5→ E3 + P (3.2)
E2
k6→ E4
E3
k7→ E4
E4
k8→ E1
with the following variable definitions:
• E1 = Fe(I I I) = POX PGHS
• E2 = Fe(IV)PP• = PGHS intermediate 1
• E3 = Fe(IV)Tyr• = COX PGHS
• E4 = Fe(IV) = PGHS intermediate 2
• P = PGG2
• H = PGH2
• S = AA = arachidonic acid
• C1 = Fe(IV)AA•/Tyr = PGHS-arachidonic acid complex 1, or PGHS-
AA complex 1
• C2 = Fe(IV)AAO2•/Tyr = PGHS-arachidonic acid complex 2, or
PGHS-AA complex 2.
From Bambai and Kulmacz (2000), we added in suicide inactivation of
the COX site
E3
k9→ E5, (3.3)
where E3 is the COX PGHS and E5 is inactive PGHS. Using information
provided by Goltsov et al. (2010), we derived a chemical reaction equation
for aspirin:
E∗ + A
kon,aspirin−→ Cˆ, (3.4)
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where A denotes aspirin and Cˆ is the PGHS-aspirin complex. Let kon,aspirin
be called k10.
From Wang et al. (2001), we deduced the relationship between PGH2
and thromboxane:
E6 + H → X → B, (3.5)
where E6 is thromboxane A synthase, H is PGH2, X is TXA2, and B is throm-
boxane B2, or TXB2. The proposed mechanism for the production of TXA2
and TXB2 (Wang et al., 2001) is
E6 + H
ka
k−a
E′ : H
kb
k−b
C′
C′
kc
k−c
HHT (3.6)
C′
kd
k−d
X,
where C′ is the enzyme-substrate complex and HHT is a side product.
The rate constants k−b, k−c, and k−d were set to equal 0.01 s−1, making
the corresponding reactions essentially irreversible, after which it was ex-
perimentally determined that the reaction with rate constant ka is the rate-
determining, and therefore slowest, step (Wang et al., 2001). We therefore
simplified Equation 3.6 into
E6 + H
ka→ X. (3.7)
However, TXA2 has a very short half-life, and when in aqueous solutions,
it is almost immediately converted to the inactive TXB2 (Wang et al., 2001).
Thus, we made the following simplification:
E6 + H
ka→ B, (3.8)
and defined ka as k11. The reaction was written to be irreversible, because
we would never see TXB2 converting to TXA2, due to the labile nature of
TXA2.
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We combined Equations 3.2, 3.3, 3.4, and 3.8 together to get:
E1 + P
k1→ E2 + H
E2
k2→ E3
E3 + S
k3→ C1 k4→ C2 k5→ E3 + P
E2
k6→ E4
E3
k7→ E4 (3.9)
E4
k8→ E1
E3
k9→ E5
E3 + A
k10→ C3
E6 + H
k11→ E6 + B.
Converting these chemical equations to differential equations yielded
E˙1 = −k1E1P + k8E4
E˙2 = k1E1P− E2 (k2 + k6)
E˙3 = k2E2 + k5C2 − E3 (k3S + k7 + k9 + k10A)
E˙4 = k6E2 + k7E3 − k8E4
E˙5 = k9E3
E˙6 = 0
C˙1 = k3E3S− k4C1 (3.10)
C˙2 = k4C1 − k5C2
C˙3 = k10E3A
P˙ = −k1E1P + k5C2
H˙ = k1E1P− k11E6H
A˙ = −k10E3A
S˙ = −k3E3S
B˙ = k11E6H
where E˙1 denotes the rate of change of E1 with respect to time, or dE1dt , and
so on.
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3.2 Initial Concentration and Rate Constant Values
In order to run simulations in MATLAB, numerical values were needed for
initial concentrations of all enzymes and their alternate forms, complexes,
reactants, and product and for the reaction rates.
3.2.1 Initial Conditions
Initial concentrations for POX PGHS (E1), COX PGHS (E3), and arachidonic
acid, or AA, (S) were found in Goltsov et al. (2010). We ran our simulations
with an aspirin dosage of 325 mg; this dosage was chosen so that we had
a corresponding expected final concentration of TXB2 from Feldman and
Cryer (1999) that could be measured. Using a molar mass of 180.157 g/mol,
the volume of distribution for aspirin of 0.2 L/kg (McEvoy, 2007), and a
mass of 83 kg, which was the mean weight of the subjects from Feldman’s
experiment (1999), we obtained an initial concentration of 1.0867× 10−4 M
for aspirin (A). As for the thromboxane B2 (B) value, data from Feldman
and Cryer (1999) gave us an initial concentration of 1.7545× 10−6 M that
was converted from the reported 650 ng/mL using a molar mass of throm-
boxane B2 of 370.48 g/mol.
Variables Initial values (M) Sources
E1 (POX PGHS) 10−8 − 10−6 Goltsov et al., 2010
E2 (PGHS intermediate 1) 10−8 − 10−6
E3 (COX PGHS) 10−8 − 10−6 Goltsov et al., 2010
E4 (PGHS intermediate 2) 10−8 − 10−6
E5 (Inactive PGHS) 0
E6 (Thromboxane A synthase) 10−8 − 10−6
C1 (PGHS-AA complex 1) 0
C2 (PGHS-AA complex 2) 0
C3 (PGHS-aspirin complex) 0
P (PGG2) 0 Gerrard et al., 1977
H (PGH2) 0 Gerrard et al., 1977
A (Aspirin) 1.0867× 10−4 Feldman and Cryer, 1999
S (Arachidonic acid) 10−9 − 10−7 Goltsov et al., 2010
B (TXB2) 1.7545× 10−6 Feldman and Cryer, 1999
Table 3.1 Initial concentrations for all enzymes, reactants, and products.
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Values for the remaining variables could not be found in literature and
were deduced from alternate research. Initial concentration values for PGHS
intermediates 1 (E2) and 2 (E4) were set to be equal to the initial concentra-
tion values for POX and COX PGHS due to the chemical nature of enzymes.
They are not four different enzymes, but rather one enzyme with different
forms and sites of catalysis that perform different functions. Initial con-
centration values for PGHS-AA complexes 1 (C1) and 2 (C2), PGHS-aspirin
complex (C3), and inactive PGHS (E5) was set to be 0 M, because the reac-
tions had not yet occurred at time t = 0 s. Data for the initial concentration
value of thromboxane A synthase could not be found, and so we will as-
sume a value equal to that of the PGHS forms. PGG2 and PGH2 are short-
lived and labile, and under normal conditions will be quickly metabolized
to form other products; thus, they cannot be isolated, and their concentra-
tions are immeasurable, as they are quickly used in a reaction once they
are formed (Gerrard et al., 1977). Therefore, initial concentration values for
PGG2 (P) and PGH2 (H) were both 0 M. Table 3.1 provides a consolidated
summary of all initial concentration values.
3.2.2 Expected Values
In order to prove the validity of our model, we wanted to see if our sim-
ulated expected value of TXB2 matches an experimental value. Feldman
and Cryer (1999) experimentally determined that the concentration level
of TXB2 was 100 ng/mL 30 minutes after ingestion of a 325-mg tablet of
aspirin. We converted this value to 2.70× 10−7 M using a molar mass of
370.48 g/mol. We proved the validity of our model by running simulations
in Section 5.2.2.
3.2.3 Rate Constants
Values for reaction rates k1 through k8 were given by Wei et al. (1995), k9 by
Bambai and Kulmacz (2000), k10 by Goltsov et al. (2010), and k11 by Wang
et al. (2001). These values are summarized in Table 3.2. However, some of
these reaction rates were faulty, due to the simplification of our model from
the model proposed by Wei et al. (1995).
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Rate constants Values Units Source
k1 1× 108 M−1s−1 Wei et al., 1995
k2 350 s−1 Wei et al., 1995
k3 1× 106 M−1s−1 Wei et al., 1995
k4 ≥ 5× 106 M−1s−1 Wei et al., 1995
k5 ≥ 5× 106 M−1s−1 Wei et al., 1995
k6 ≤ 3.5× 106 M−1s−1 Wei et al., 1995
k7 (0.5− 5)× 106 M−1s−1 Wei et al., 1995
k8 5.5× 106 M−1s−1 Wei et al., 1995
k9 5× 10−2 s−1 Bambai and Kulmacz, 2000
k10 10M−1 s−1 Goltsov et al., 2010
k11 (1.2− 2.0)× 107 M−1s−1 Wang et al., 2001
Table 3.2 Values for all rate constants.
Rate constants were determined experimentally by determining the rate
of the reaction and dividing that by the concentrations of the reactants (cf.
Nelson and Cox, 2012). For example, given a general chemical reaction
A + B k→ C + D, (3.11)
the reaction rate is as follows:
Reaction rate = k[A][B], (3.12)
where the brackets denote “concentration of.” Therefore, the rate constant
can be calculated as such:
k =
reaction rate
[A][B]
. (3.13)
For reactions governed by rate constants k4 through k8, Wei et al. (1995)
proposed reactions with two reactants, whereas we proposed reactions with
only one reactant. Thus, the values and units for rate constants k4 through
k8 are compromised. We accommodated for this by finding a value for nor-
mal blood concentration levels of oxygen by which we could scale k4 and
k5. However, multiplying our rate constants by this value did not yield the
expected final concentration of TXB2. Values for normal blood concentra-
tion levels of ferulic acid, by which we would have scaled k6, k7, and k8,
could not be found. Therefore, we scaled these rate constants by multiply-
ing them by arbitrary scalars with units of M. Rate constants k4 and k5 were
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scaled by the same factor (0.4), since the same reactant was omitted from
both corresponding reactions in our simplified model, and rate constants
k6 through k8 were scaled by the same factor (500), for the same reason.
Rate constants Values Units
k1 1× 108 M−1s−1
k2 350 s−1
k3 1× 106 M−1s−1
k4 2.0× 106 s−1
k5 2.0× 106 s−1
k6 1.75× 109 s−1
k7 1.0× 109 s−1
k8 2.75× 109 s−1
k9 5× 10−2 s−1
k10 10 M−1s−1
k11 1.5× 107 M−1s−1
Table 3.3 List of rate constants to be used in MATLAB simulations.
Chapter 4
Reduced model
Following the style of Tien et al. (2005), we thought it would be useful to
simplify our model and perform a stability analysis on our model. Such an
analysis would tell us when the reactions of PGHS would be self-sustaining
and when they would cease. Furthermore, simplification of the model
would allow it to be more easily integrable into other models of blood clot-
ting. We also ran simulations of our model to see if it would match experi-
mental data found by Feldman and Cryer (1999).
4.1 Reduction
We begin with our chemical model, Equation 3.9 derived in Section 3.1:
E1 + P
k1→ E2 + H (4.1)
E2
k2→ E3 (4.2)
E3 + S
k3→ C1 k4→ C2 k5→ E3 + P (4.3)
E2
k6→ E4 (4.4)
E3
k7→ E4 (4.5)
E4
k8→ E1 (4.6)
E3
k9→ E5 (4.7)
E3 + A
k10→ C3 (4.8)
E6 + H
k11→ E6 + B (4.9)
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We combined Equation 4.1 and Equation 4.2 to obtain
E1 + P
k1→ E2 k2→ E3 + H, (4.10)
and reduced Equation 4.3 to
E3 + S
k3→ C1 k5→ E3 + P, (4.11)
and combined Equation 4.5 and Equation 4.6 to obtain
E3
k7→ E1. (4.12)
Equations 4.7, 4.8, and 4.9 remained the same, and Equation 4.4 was not
factored into the reduced model.
Equations 4.7-4.11 came together to form a reduced model:
E1 + P
k1→E2 k2→ E3 + H
E3 + S
k3→C1 k5→ E3 + P
E3
k7→ E1 (4.13)
E3
k9→ E5
E3 + A
k10→ C3
E6 + H
k11→ E6 + B
with the following corresponding differential equations:
E˙1 = k7E3 − k1E1P
E˙2 = k1E1P− k2E2
E˙3 = k2E2 + k5C1 − k3E3S− k7E3 − k9E3 − k10E3A
E˙5 = k9E3
E˙6 = 0
C˙1 = k3E3S− k5C1 (4.14)
C˙3 = k10E3A
P˙ = k5C1 − k1E1P
H˙ = k2E2 − k11E6H
A˙ = −k10E3A
S˙ = −k3E3S
B˙ = k11E6H
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4.2 Stability Analysis
We performed a stability analysis on the fixed points of the reduced system
for general rate constants, ki, where i = 1, 2, ..., 11.
4.2.1 Finding the Fixed Points
We began the stability analysis with the following assumptions:
• S (arachidonic acid) is fixed, and
• k9 = 0, eliminating suicide inactivation of PGHS.
We defined Eo to be the sum of all forms, intermediates, and complexes of
PGHS:
Eo = E1 + E3 + E2 + C1 (4.15)
and therefore defined E1 as
E1 = Eo − E3 − E2 − C1 (4.16)
and eliminated E1 (POX PGHS) from the system by replacing E1 with the
above expression. We argued that B (TXB2) and C3 (PGHS-aspirin complex)
did not contribute to the stability of any fixed points, since they do not
appear on the right-hand side of any of the differential equations. We were
then left with the following system of differential equations:
E˙3 = k2E2 + k5C1 − E3 (k3S + k7 + k10A)
E˙6 = 0
E˙2 = k1 (Eo − E3 − E2 − C1) P− k2E2
C˙1 = k3E3S− k5C1 (4.17)
P˙ = k5C1 − k1 (Eo − E3 − E2 − C1) P
H˙ = k2E2 − k11E6H
A˙ = −k10E3A
with fixed points of the form
(E3, E6, E2, C1, P, H, A) . (4.18)
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Setting each of the differential equations to zero gave us the following
fixed points:
(0, 0, 0, 0, 0, 0, 0)
(0, E6, 0, 0, 0, 0, 0)
(0, 0, 0, 0, P, 0, 0)
(0, 0, 0, 0, 0, H, 0)
(0, 0, 0, 0, 0, 0, A)
(0, E6, 0, 0, P, 0, 0)
(0, E6, 0, 0, 0, 0, A)
(0, 0, 0, 0, P, H, 0)
(0, 0, 0, 0, P, 0, A)
(0, 0, 0, 0, 0, H, A)
(0, E6, 0, 0, P, 0, A)
(0, 0, 0, 0, P, H, A).
From our fixed points, we know that E3, E2, and C1 = 0, making E0 = E1.
If E0 = E1 = 0, then there are no PGHS molecules present in the system,
leaving P (PGG2) unchanged. However, if we perturb Eo to be greater than
0, and therefore E1 > 0, then P might be affected, depending on its value. If
P = 0, then it remains unchanged after the perturbation. On the other hand,
when P is initially fixed at some value greater than zero, perturbations to
Eo, and consequently to E1, will cause the value of P to perturb away from
that initial fixed value. Therefore, the following fixed points
(0, 0, 0, 0, P, 0, 0)
(0, E6, 0, 0, P, 0, 0)
(0, 0, 0, 0, P, H, 0)
(0, 0, 0, 0, P, 0, A)
(0, E6, 0, 0, P, 0, A)
(0, 0, 0, 0, P, H, A) ,
with P > 0, are always unstable. The stability of the remaining fixed points
(0, 0, 0, 0, 0, 0, 0)
(0, E6, 0, 0, 0, 0, A)
(0, 0, 0, 0, 0, H, A)
(0, E6, 0, 0, 0, 0, 0)
(0, 0, 0, 0, 0, H, 0)
(0, 0, 0, 0, 0, 0, A)
will be determined next.
4.2.2 The Generalized Jacobian Matrix
Because the equations were linearizable, we were able to construct the Ja-
cobian matrix for our system, for a general fixed point of the form
(0, E6, 0, 0, 0, H, A):
J =

−k3S− k7 − k10A 0 k2 k5 0 0 0
0 0 0 0 0 0 0
0 0 −k2 0 k1Eo 0 0
k3S 0 0 −k5 0 0 0
0 0 0 k5 −k1Eo 0 0
0 −k11H k2 0 0 −k11E6 0
−k10A 0 0 0 0 0 0

.
(4.19)
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4.2.3 Stability of (0, 0, 0, 0, 0, 0, 0) and (0, 0, 0, 0, 0, H, 0)
We determined the stability of the fixed point (0, 0, 0, 0, 0, 0, 0) by evaluating
the Jacobian at (0, 0, 0, 0, 0, H, 0):
J0 =

−k3S− k7 0 k2 k5 0 0 0
0 0 0 0 0 0 0
0 0 −k2 0 k1Eo 0 0
k3S 0 0 −k5 0 0 0
0 0 0 k5 −k1Eo 0 0
0 0 k2 0 0 0 0
0 0 0 0 0 0 0

. (4.20)
The characteristic polynomial of Equation 4.20 is
p (λ) = λ7 + a1λ6 + a2λ5 + a3λ4 + a4λ3, (4.21)
where
• a1 = k1Eo + k2 + k3S + k5 + k7
• a2 = k3S (k2 + k1Eo) + k1Eo (k2 + k5 + k7) + k7 (k2 + k5) + k2k5
• a3 = k1Eo [(k2 + k5) (k7) + k2 (k5 + k3S)] + k2k5k7, and
• a4 = k1k2k5Eo (k7 − k3S).
The Jacobian matrix for (0, 0, 0, 0, 0, H, 0) is
JH =

−k3S− k7 0 k2 k5 0 0 0
0 0 0 0 0 0 0
0 0 −k2 0 k1Eo 0 0
k3S 0 0 −k5 0 0 0
0 0 0 k5 −k1Eo 0 0
0 −k11H k2 0 0 0 0
0 0 0 0 0 0 0

, (4.22)
and it resulted in the same characteristic polynomial as that of the zero
fixed point. Although Equation 4.22 did not appear to be linearized due
to the −k11H term, we took any variables that were still remaining after
the linearization and treat them as fixed-value parameters, in the hopes
of basing the stability of the fixed point on functions of those variables.
However, this was deemed unnecessary in this case, as the nonlinear term
in question did not affect the characteristic polynomial.
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We used a summary from the Routh-Hurwitz Theorem to determine the
stability of these fixed points, and the criteria were as follows:
a1 > 0
a3 > 0
a4 > 0
a1a2a3 > a32 + a12a4,ora1a2a3 − a32 + a12a4 > 0
(Allen, 2006). More information on the Routh-Hurwitz Theorem can be
found in Appendix A. Because k1, k2, k3, k5, k7, Eo, and S all take on positive
values, we know that a1 and a3, both of which are comprised of sums of
positive numbers, are both greater than zero.
Furthermore, if we multiply out, expand, and simplify the expression
a1a2a3 − a32 − a12a4, we can see that it consists of sums of only positive
terms, satisfying the last criterion.
Thus, the stability of the zero fixed point only depends on a4.
For a4 to be greater than zero, we need
k1k2k5Eo (k7 − k3S) > 0
k7 − k3S > 0.
Keeping in the same style as Tien et al. (2005), we have
k3S < k7
k3S
k7
< 1
k3S
k7
− 1 < 0.
We define
σ =
k3S
k7
− 1, (4.23)
where the stability of the zero fixed point is dependent on the sign of σ,
with σ < 0 indicating a stable fixed point and σ ≥ 0 indicating an unstable
point.
4.2.4 Implications of the Stability of
(0, 0, 0, 0, 0, 0, 0) and (0, 0, 0, 0, 0, H, 0)
We then analyzed the requirements for stability of the fixed points
(0, 0, 0, 0, 0, 0, 0) and (0, 0, 0, 0, 0, H, 0) and the biological consequences. The
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fixed points and their stability were determined under the conditions that
S was fixed and suicide inactivation was not present. The next section dis-
cusses the analysis of such stability, and the two sections after discuss the
implications when these conditions are not met.
The analyses discuss the conditions under which the reactions carried
out by PGHS would be self-sustaining and the conditions under which the
reactions would terminate. This information could be useful in finding ap-
propriate dosages of aspirin required to prevent blood clotting—sufficient
to induce unwanted blood clotting while avoiding health complications
that could accompany an overdose or undesired side effects.
S is Fixed, Suicide Inactivation is Absent
With arachidonic acid concentration fixed and enzyme suicide inactiva-
tion absent, the only factors that could affect whether or not PGHS is self-
sustaining are the PGG2 and aspirin concentrations.
As in the case of Tien et al. (2005), we ran simulations with varying
rate constants that produced situations where σ was greater than zero and
less than zero. A value of σ greater than zero indicated that rate of PGG2
production was larger than the rate of consumption or that the rate of COX
PGHS consumption by aspirin was negligible, thus keeping PGG2 in the
system and allowing the reactions to be self-sustaining. A value of σ less
than zero indicated that the rate of PGG2 consumption was larger than the
rate of production, leading to a removal of PGG2 from the system, or that
the rate of COX PGHS consumption by aspirin was significant enough to
remove PGHS from the system. Either situation would lead to cessation of
PGHS activity.
S Can Vary
The likelihood that the arachidonic acid concentration is fixed is quite small,
as our bodies and cells are constantly producing and using chemicals, in-
cluding arachidonic acid. We concluded that if arachidonic acid concentra-
tion levels were allowed to vary, then PGHS activity would be terminated if
there was no constant addition of arachidonic acid in the system, and PGHS
activity would be self-sustaining if arachidonic acid was always supplied
for the system.
22 Reduced model
Suicide Inactivation is Present
We hypothesized that if COX PGHS were to undergo suicide inactivation,
then it would potentially remove itself from the system entirely, if aspirin
consumption of COX PGHS did not already do so. Thus, the reactions mod-
eled by our system could come to a halt through enzyme inactivation; how-
ever, this phenomenon would be dependent on the rate constant and initial
concentration values.
4.2.5 Stability of (0, 0, 0, 0, 0, 0, A), (0, 0, 0, 0, 0, H, A), (0, E6, 0, 0, 0, 0, 0),
(0, E6, 0, 0, 0, 0, A)
In this section, we will discuss the stability of the remaining fixed points:
(0, 0, 0, 0, 0, 0, A)
(0, 0, 0, 0, 0, H, A)
(0, E6, 0, 0, 0, 0, 0)
(0, E6, 0, 0, 0, 0, A)
The Jacobian matrices for the above points are provided in this section.
However, due to the complexity and length of the expressions that resulted
from the Routh-Hurwitz Criterion summaries (Allen, 2006), we will merely
state that the stabilities of each of these fixed points are heavily dependent
on the values of the rate constants, S, and Eo, and will be functions of A, E6,
or both. We also noted that the characteristic polynomial of Equation 4.24
was the same as that of Equation 4.25, so we were left with three character-
istic polynomials from which we could determine the stability of the four
corresponding fixed points. These stability criteria are detailed in Appen-
dix B, and they can be used with specific rate constants to determine the
stability of these fixed points for those particular rate constant values.
The Jacobian matrix at (0, 0, 0, 0, 0, 0, A) is
JA =

−k3S− k7 − k10A 0 k2 k5 0 0 0
0 0 0 0 0 0 0
0 0 −k2 0 k1Eo 0 0
k3S 0 0 −k5 0 0 0
0 0 0 k5 −k1Eo 0 0
0 0 k2 0 0 0 0
−k10A 0 0 0 0 0 0

. (4.24)
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The Jacobian matrix at (0, 0, 0, 0, 0, H, A) is
JH,A =

−k3S− k7 − k10 A 0 k2 k5 0 0 0
0 0 0 0 0 0 0
0 0 −k2 0 k1Eo 0 0
k3S 0 0 −k5 0 0 0
0 0 0 k5 −k1Eo 0 0
0 −k11H k2 0 0 0 0
−k10A 0 0 0 0 0 0

. (4.25)
The Jacobian matrix at (0, E6, 0, 0, 0, 0, 0) is
JE6 =

−k3S− k7 0 k2 k5 0 0 0
0 0 0 0 0 0 0
0 0 −k2 0 k1Eo 0 0
k3S 0 0 −k5 0 0 0
0 0 0 k5 −k1Eo 0 0
0 −k11H k2 0 0 −k11E6 0
0 0 0 0 0 0 0

. (4.26)
Lastly, the Jacobian matrix at (0, E6, 0, 0, 0, 0, A) is
JE6,A =

−k3S− k7 − k10A 0 k2 k5 0 0 0
0 0 0 0 0 0 0
0 0 −k2 0 k1Eo 0 0
k3S 0 0 −k5 0 0 0
0 0 0 k5 −k1Eo 0 0
0 0 k2 0 0 −k11E6 0
−k10A 0 0 0 0 0 0

.
(4.27)
We can come to similar types of conclusions for these points as we did
for the fixed points (0, 0, 0, 0, 0, 0, 0) and (0, 0, 0, 0, 0, H, 0), using the results
from Appendix B.
4.3 Simulations
We used the initial concentrations and rate constants from Section 3.2 and
ran simulations of our model in MATLAB using the stiff solver ode23s to
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plot the concentration-time curve of TXB2 over 30 minutes. We ran simu-
lations with and without aspirin; we expected the concentration of TXB2
to remain unchanged without aspirin and to decrease to 2.70× 10−7 M, as
determined in section 3.2.
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Figure 4.1 Concentration-time curve for TXB2, with and without aspirin for the
reduced system, with rate constants from Section 3.2.
When we used the original rate constants, the TXB2 concentration in-
creased from its starting concentration of 1.7545× 10−6 M to a steady state
value of 2.63 × 10−6 M for both the cases with and without aspirin, as
shown in Figure 4.1, where the box depicts the initial concentration.
We then altered k11, by multiplying it by 10−17, in an attempt to bring
the TXB2 concentration down to the expected value; this was not success-
ful, however, and while we were able to make both cases result in an un-
changed TXB2 concentration, we were unable to manipulate the case with
aspirin therapy into decreasing towards the expected final concentration,
as can be seen in Figure 4.2, where the box denotes the initial concentra-
tion. Therefore, we hypothesize that an important piece of the model was
omitted during the reduction of our system.
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Figure 4.2 Concentration-time curve for TXB2, with and without aspirin for the
reduced system, with altered rate constants.
We concluded that while the reduced system did offer insight into the
terms of self-sustainment for PGHS, it did not accurately model the effect
of aspirin on blood clotting. Therefore, we revisited the full model and
performed similar analyses and simulations.

Chapter 5
Full Model
The simulations for the reduced model did not yield accurate representa-
tion of the interaction between PGHS and aspirin to result in unwanted
blood clotting. Therefore, we analyzed the full system for stability and ran
simulations.
5.1 Stability Analysis
We begin this section by reminding our readers of our system of equations:
E˙1 = −k1E1P + k8E4
E˙2 = k1E1P− E2 (k2 + k6)
E˙3 = k2E2 + k5C2 − E3 (k3S + k7 + k9 + k10A)
E˙4 = k6E2 + k7E3 − k8E4
E˙5 = k9E3
E˙6 = 0
C˙1 = k3E3S− k4C1 (5.1)
C˙2 = k4C1 − k5C2
C˙3 = k10E3A
P˙ = −k1E1P + k5C2
H˙ = k1E1P− k11E6H
A˙ = −k10E3A
S˙ = −k3E3S
B˙ = k11E6H
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with the following variable definitions:
• E1 = POX PGHS
• E2 = PGHS intermediate 1
• E3 = COX PGHS
• E4 = PGHS intermediate 2
• E5 = inactive PGHS
• C1 = PGHS-AA complex 1
• C2 = PGHS-AA complex 2
• C3 = PGHS-aspirin complex
• P = PGG2
• H = PGH2
• A = aspirin
• S = arachidonic acid, or AA
• B = TXB2
We performed a stability analysis on the fixed points of Equation 3.10.
However, due to the long and complex computations, we will provide the
reader with the fixed points and the corresponding linearized equations
and Jacobian matrices and direct the reader to Appendix B.
5.1.1 Finding the Fixed Points
To begin the stability analysis, we first assumed that
• S (arachidonic acid) is fixed, and
• k9 = 0, eliminating suicide inactivation of PGHS.
We defined Eo to be the sum of all forms, intermediates, and complexes of
PGHS:
Eo = E1 + E3 + E2 + E4 + C1 + C2 (5.2)
and therefore defined E1 as
E1 = Eo − E3 − E2 − E4 − C1 − C2 (5.3)
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and eliminated E1 (POX PGHS) from the system by replacing E1 with the
above expression. We argued that B (TXB2) and C3 (PGHS-aspirin complex)
did not contribute to the stability of any fixed points, since they do not
appear on the right-hand-side of any of the differential equations. We were
then left with the following system of differential equations:
E˙3 = k2E2 + k5C1 − E3 (k3S + k7 + k10A)
E˙6 = 0
E˙2 = k1 (Eo − E3 − E2 − E4 − C1 − C2) P− E2 (k2 + k6)
E˙4 = k7E3 + k6E2 − k8E4
C˙1 = k3SE3 − k4C1 (5.4)
C˙2 = k4C1 − k5C2
P˙ = k5C2 − k1 (Eo − E3 − E2 − E4 − C1 − C2) P
H˙ = k1 (Eo − E3 − E2 − E4 − C1 − C2) P− k11E6H
A˙ = −k10E3A
with fixed points of the form
(E3, E6, E2, E4, C1, C2, P, H, A) . (5.5)
Setting each of the differential equations to zero gave us the following
fixed points:
(0, 0, 0, 0, 0, 0, 0, 0, 0)
(0, E6, 0, 0, 0, 0, 0, 0, 0)
(0, 0, 0, 0, 0, 0, P, 0, 0)
(0, 0, 0, 0, 0, 0, 0, H, 0)
(0, 0, 0, 0, 0, 0, 0, 0, A)
(0, E6, 0, 0, 0, P, 0, 0, 0)
(0, E6, 0, 0, 0, 0, 0, 0, A)
(0, 0, 0, 0, 0, 0, P, H, 0)
(0, 0, 0, 0, 0, 0, P, 0, A)
(0, 0, 0, 0, 0, 0, 0, H, A)
(0, E6, 0, 0, 0, 0, P, 0, A)
(0, 0, 0, 0, 0, 0, P, H, A)
From our fixed points, we know that E3, E2, E4, C1, and C2 = 0, making
E0 = E1. If E0 = E1 = 0, then there are no PGHS molecules present in
the system, leaving P (PGG2) unchanged. However, if we perturb Eo to be
greater than 0, and therefore E1 > 0, then P might be affected, depending
on its value. If P = 0, then it remains unchanged after the perturbation. On
the other hand, for some fixed value of P > 0, perturbations to Eo, and E1,
will perturb P away from that initial fixed value. Therefore, the following
fixed points
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(0, 0, 0, 0, 0, 0, P, 0, 0)
(0, E6, 0, 0, 0, P, 0, 0, 0)
(0, 0, 0, 0, 0, 0, P, H, 0)
(0, 0, 0, 0, 0, 0, P, 0, A)
(0, E6, 0, 0, 0, 0, P, 0, A)
(0, 0, 0, 0, 0, 0, P, H, A)
with P > 0 are always unstable. The stability of the remaining fixed points
(0, 0, 0, 0, 0, 0, 0, 0, 0)
(0, 0, 0, 0, 0, 0, 0, H, 0)
(0, E6, 0, 0, 0, 0, 0, 0, A)
(0, 0, 0, 0, 0, 0, 0, H, A)
(0, E6, 0, 0, 0, 0, 0, 0, 0)
(0, 0, 0, 0, 0, 0, 0, 0, A)
will be determined next.
5.1.2 Stability of the Fixed Points
The generalized Jacobian matrix for our full system is provided in this sec-
tion. However, due to the complexity of the expressions that result from the
Routh array (Co, 1999) and the Routh Hurwitz Theorem (Allen, 2006), we
will merely state that the stabilities of each of these fixed points are heavily
dependent on the values of the rate constants, S, and Eo, and some will be
functions of A, E6, or both. These stability criteria are detailed in Appendix
C, along with the Jacobian matrices for each of the fixed points.
The generalized Jacobian matrix for a fixed point of the form
(0, E6, 0, 0, 0, 0, 0, H, A) is
J =

−k3S− k7 − k10A 0 k2 0 0 k5 0 0 0
0 0 0 0 0 0 0 0 0
0 0 −k2 − k6 0 0 0 k1Eo 0 0
k7 0 k6 −k8 0 0 0 0 0
k3S 0 0 0 −k4 0 0 0 0
0 0 0 0 k4 −k5 0 0 0
0 0 0 0 0 k5 −k1Eo 0 0
0 −k11H 0 0 0 0 k1Eo −k11E6 0
−k10A 0 0 0 0 0 0 0 0

.
(5.6)
Using the results found in Appendix C, we can still find the conditions
under which PGHS is self-sustaining and under which its reactions termi-
nate; again, this information can be used to give insights into appropriate
aspirin dosage.
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5.2 Simulations
We ran simulations of our full model in MATLAB using the stiff solver
ode23s to plot the concentration of TXB2 over a time period of 30 minutes,
both with and without aspirin.
5.2.1 Rate Constants
We used the initial concentrations listed in Sections 5.2 to run our simu-
lations in MATLAB. However, our simulations did not match the expected
final concentration for thromboxane B2 given by Feldman and Cryer (1999),
and so rate constants k1 and k10 were also adjusted and multiplied by 0.085
and 0.999000305, respectively. Some of the rate constants found in the liter-
ature were reported as ranges, so we picked arbitrary values from those
ranges. Table 5.1 summarizes the rate constants that were used in our
simulations in MATLAB to yield an expected TXB2 final concentration of
2.70× 10−7 M.
Rate constants Values Units
k1 8.5× 106 M−1s−1
k2 350 s−1
k3 1× 106 M−1s−1
k4 2.0× 106 s−1
k5 2.0× 106 s−1
k6 1.75× 109 s−1
k7 1.0× 109 s−1
k8 2.75× 109 s−1
k9 5× 10−2 s−1
k10 9.99000305 M−1s−1
k11 1.5× 107 M−1s−1
Table 5.1 List of rate constants used in MATLAB simulation for the full system.
5.2.2 MATLAB Simulations
Without aspirin present, we would expect the concentration of TXB2 to re-
main unchanged. This was supported by our simulation. Figure 5.1 shows
the change in concentration of TXB2 over 30 minutes, where the box denotes
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the initial concentration. As predicted, the figure shows that the concentra-
tion level does not change over time when there is no aspirin present and
remains at 1.7545× 10−6 M.
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Figure 5.1 Concentration-time curve for TXB2 without aspirin.
Due to the competitive nature of aspirin as an inhibitor, if the concen-
tration of aspirin is much larger than that of arachidonic acid, then COX
PGHS should not be reacting with arachidonic acid at all. However, MAT-
LAB does not take this into account. Therefore, in our simulations with
aspirin present, we implemented an if-statement such that the following
occured:
If [A] > [S]:
E˙3 = k2E2 + k5C2 − E3 (k9 + k10A) (5.7)
Else:
E˙3 = k2E2 + k5C2 − E3 (k3S + k7 + k9)
In the “if” clause, we eliminated the reaction of COX PGHS with arachi-
donic acid to form PGHS complex 2 and the conversion of COX PGHS into
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PGHS intermediate 2. In the “else” clause, we eliminated the reaction of
COX PGHS with aspirin. Suicide inactivation was present in both situa-
tions.
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Figure 5.2 Concentration-time curve for TXB2 with aspirin.
Figure 5.2 shows the concentration-time curve for TXB2 for 30 minutes
that was generated by our MATLAB simulation, where the box depicts the
initial concentration. The final concentration of TXB2 equaled 2.5× 10−7 M,
which was close to the predicted final concentration of TXB2 of 2.70× 10−7
M from Feldman and Cryer (1999).
We noted that the shape of our graph did not match the data of Feldman
and Cryer (1999), as the concentration of TXB2 decays at a much quicker
rate. Feldman and Cryer reported that the TXB2 concentration did not hit
the final value of 2.70× 10−7 M until 30 minutes after aspirin ingestion; at
one minute after ingestion, 5 minutes, and 7.5 minutes, the TXB2 concen-
trations were 1.552× 10−6 M, 1.417× 10−6 M, and 1.215× 10−6 M, respec-
tively (1999). However, our simulations showed a decrease to 2.5× 10−7 M
well before one minute after aspirin ingestion. There was neither sufficient
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chemical data nor assays to determine what would cause such a rapid de-
cay. Therefore, we hypothesized that other factors are feeding into TXB2,
that cause the slower decrease, that are not included in our model. We also
noted that despite not capturing the transient response over the 30-minute
time period, we ultimately did achieve an accurate steady state concentra-
tion of TXB2 of 2.5× 10−7 M, which is vital for preventing unwanted blood
clotting.
5.3 Sensitivity Analysis
The failure of the rate constants to produce the expected final concentration
of TXB2 without alteration lead us to perform a sensitivity analysis on our
system.
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Figure 5.3 Sensitivity Analysis of Paramaters of the Dimensional System.
Figure 5.3 shows the sensitivity of final TXB2 concentration in relation
to the sensitivity of the rate constants. We can see that the rate constants
with the highest effect on the final TXB2 concentration were k2, k3, k6, and
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k10, with k7 and k8 having the next largest effects. Although an order of
magnitude of 10−7 for the percent changes in concentration may seem triv-
ial, these percentages actually reflect a large change on our system, given
that the rate constants were on a similar order of magnitude. For a better
sense of the relative change, another sensitivity analysis was performed on
a nondimensionalized version of our system in Section 5.4
5.4 Nondimensionalization
We performed a nondimensionalization in order to simplify our system of
equations. The nondimensionalized system is as follows:
E˙1 = −E1P + λ
µ
E4
E˙2 = αE1P− βE2
E˙3 = σηE2 +
1
α
C2 − E3 (S + γ+ δ+ A)
E˙4 = ηE2 + σµγE3 − λE4
E˙5 = κE3
E˙6 = 0
C˙1 = µE3S− ηC1 (5.8)
C˙2 = ρC1 − C2
C˙3 = µE3A
P˙ = −eE1P + η
σ
C2
H˙ = θE1P− E6H
A˙ = κE3A
S˙ = −ρE3S
B˙ = φE6H
with the following unit-less coefficients:
• α = k2k4
• β = k2+k6k5
• σ = k3k1
• γ = k7k5
• δ = k9k5
• η = k4k5
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• λ = k8k5
• κ = k2k10k3k5
• µ = k2k5
• ρ = k6k5
• e = k2k5
• θ = k11k1
• φ = k10k11
5.4.1 Simulations
The results for the final concentration value of TXB2 for the nondimension-
alized system was the same as those for the dimensionalized system for
both the case without aspirin and the case with aspirin.
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Figure 5.4 Concentration-time curve for TXB2 without aspirin in the nondimen-
sionalized system.
This can be seen in Figure 5.4 and Figure 5.5, where the boxes denote the
initial concentrations. As in the dimensionalized system, running the sim-
ulation without aspirin resulted in no change in the concentration of TXB2,
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Figure 5.5 Concentration-time curve for TXB2 with aspirin in the nondimen-
sionalized system.
and running the simulation with aspirin resulted in a steady state TXB2
concentration of 2.5× 10−7 M.
5.4.2 Sensitivity Analysis
We also performed a sensitivity analysis on our nondimensionalized sys-
tem, as seen in Figure 5.6, which showed that the nondimensional param-
eters with the largest effect on the final concentration of TXB2 were λ and
λ
µ . Considering that λ is
k8
k5
and that λµ is
k8
k2
, this seemed reasonable; in the
dimensionalized system, k2 had the largest impact on TXB2 concentration
and k8 had a moderate impact. With the system nondimensionalized, the
order of magnitude of the percent change in TXB2 concentration is now 10,
reflecting the order of magnitude of the new parameters.
The reaction governed by k2 is the conversion of PGHS intermediate 1
(E2) into COX PGHS (E3), and the reaction governed by k8 is the conver-
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Figure 5.6 Sensitivity Analysis of Paramaters of the Nondimensionalized Sys-
tem.
sion of PGHS intermediate 2 (E4) into POX PGHS (E1). Without COX PGHS
and POX PGHS, the reactions would not be possible, so it seems perfectly
reasonable that the rate constants that are the most sensitive correspond
to reactions that regenerate these enzymes that are crucial to the reaction
scheme. From this data, we concluded that the steady state concentration
of TXB2 is highly dependent on the rate of regeneration of both COX PGHS
and POX PGHS, enzymes that work together to produce PGH2, the precur-
sor to TXB2.
Chapter 6
Conclusion
Through this project, we were able to accomplish our main goal and de-
veloped a mathematical model that described the effect of aspirin on blood
clotting, along with running simulations based on experimental data and
analyzing the stabilities of the fixed points of the system.
6.1 Research
The research for this project was conducted through online databases. The
majority of this project was founded on research by Tien et al. (2005) and
Wei et al. (1995), who both studied and analyzed the mechanism and be-
havior of PGHS. However, neither made strong ties to blood clotting, such
as important factors like TXA2, or to aspirin therapy. Additional data and
information was required, such as the mechanism behind aspirin inhibi-
tion of PGHS and behind TXA2, and TXB2, production, experimental data
for rate constants, and standard concentration levels for all enzymes, sub-
strates, and products. All this information was synthesized into a cohesive
model of the effect of aspirin on blood clotting.
6.2 Future Work
Improvements can be made to the research and work completed through
this project, ranging from additional, necessary experimental data to fur-
ther mathematical analyses.
We lacked sufficient scientific data to accurately match the shape of
our concentration-time curve of TXB2 with aspirin therapy to experimen-
tal data. We hypothesized that there were other factors that fed into TXB2
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that might have been overlooked and insignificant in the context of blood
clotting, but would have been vital in modeling the change in TXB2 concen-
tration. Furthermore, if simulations of the reduced system were to reach an
accurate steady state concentration of TXB2, it would have important im-
plications for mathematical analyses, as the reduced system provided us
with a more detailed stability analysis and can be reduced further through
a quasi-steady-state approximation. A further reduction would allow this
model to easily integrate with other models of blood clotting, such as those
examining the dynamics of blood flow and how it leads to coagulation.
6.3 Concluding Remarks
We developed a model that tracked the enzyme prostaglandin H synthase
and its relation to blood clotting with aspirin therapy. We were able to re-
duce our system by two variables, determine the fixed points, discard some
as unstable, and capture a stability analysis for two of the remaining fixed
points of the reduced system. From this information, we determined the
the conditions under which the reactions of PGHS were self-sustaining for
three different scenarios. When arachidonic acid concentration was fixed
and suicide inactivation was absent, a stable fixed point indicated that the
reactions would ultimately terminate, and an unstable fixed point indicated
that the reactions were self-sustaining. When arachidonic acid concentra-
tion was allowed to vary and suicide inactivation was present, the termina-
tion of the reactions, or lack thereof, was dependent on the rate constants
and the additional influx of arachidonic acid into the system.
After running simulations on our reduced model and not reaching the
desired steady state TXB2 concentration, we returned to our full model,
where we set up the foundation for a stability analysis. This would tell us
when the reactions carried out by PGHS were self-sustaining, by finding the
fixed points of our system, discarding some as unstable fixed points, and
determining the stability criteria for the remaining fixed points for general
rate constant values. In addition, through simulations run on MATLAB, we
reached an accurate steady state value for TXB2 after ingestion of aspirin,
which allows us to conclude that our model captures the basis of the rela-
tionship between PGHS, TXA2, an essential blood clotting factor that was
measured in the form of TXB2, and aspirin.
The implications of this mathematical model are important for under-
standing how the degree and severity of blood clotting can be altered through
aspirin therapy. Unwanted blood clots can cause many serious health prob-
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lems, and a better understanding of how to prevent them with a common
drug such as aspirin could be beneficial in treating the health complica-
tions that accompany them. The stability analyses provides information
that could be useful for finding the ideal aspirin dosage required to prevent
undesired blood clotting; terminating the reactions of PGHS in platelets is
a preventative measure against unwanted blood clotting, and this system
provides the model with which one could determine the amount of aspirin
needed to do so. Platelet count, and therefore PGHS concentration, vary
among individuals, as do all other measurements that were used in this
project. Therefore, if the initial concentrations of these enzymes, substrates,
and products, which could be found by taking a blood test, were known for
a patient, one could use this model of aspirin’s effect on blood clotting to
determine the aspirin dosage required by that specific patient.

Appendix A
The Routh Hurwitz Theorem
The Routh Hurwitz Theorem can be used to determine the stability of fixed
points by determining if the roots of the corresponding characteristic poly-
nomial that contains only real coefficients lie in the left half of the complex
plane. If such a behavior is attained, then "any solution to the linear, homo-
geneous differential equation converges to zero" (Allen, 2006).
A.1 Routh Hurwitz Criteria
The Routh Hurwitz Criteria in its entirety, from Allen (2006), is as follows.
Theorem A.1 (Routh Hurwitz Criteria) Given the polynomial,
P(λ) = λn + a1λn−1 + · · ·+ an−1λ+ an,
where the coefficients ai are real constants, i = 1, · · · , n, define the n Hurwitz
matrices using the coefficients ai of the characteristic polynomial:
H1 = (a1) , H2 =
(
a1 1
a3 a2
)
, H3 =
 a1 1 0a3 a2 a1
a5 a4 a3
 ,
and
Hn =

a1 1 0 0 · · · 0
a3 a2 a1 1 · · · 0
a5 a4 a3 a2 · · · 0
...
...
...
... · · · ...
0 0 0 0 · · · an

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where aj = 0i f j > n. All of the roots of the polynomial P(λ) are negative or have
negative real part iff the determinants of all Hurwitz matrices are positive:
detHj > 0, j = 1, 2, · · · , n.
Allen (2006) also provided a summary of the Routh Hurwitz Critera for
n = 2, 3, 4, and 5:
n = 2 : a1 > 0 and a2 > 0
n = 3 : a1 > 0, a3 > 0, and a1a2 > a3
n = 4 : a1 > 0, a3 > 0, a4 > 0, and a1a2a3 > a32 + a12a4
n = 5 : ai > 0, i = 1, 2, 3, 4, 5, a1a2a3 > a32 + a12a4,
and (a1a4 − a5)
(
a1a2a3 − a32 − a12a4
)
> a5(a1a2 − a3)2 + a1a52.
A.2 Routh Array
An alternate way of determining the stability of fixed points is looking at
the Routh array. While we used the information provided by Co (1999) to
construct our Routh arrays, we provide the reader with a general Routh
array from Purdue School of Engineering and Technology (2007), for poly-
nomial
a0sn + a1sn−1 + · · ·+ an−1s + an = 0.
Routh array =

a0 a2 a4 a6 · · ·
a1 a3 a5 a7 · · ·
b1 b2 b3 b4 · · ·
c1 c2 c3 c4 · · ·
d1 d2 d3 d4 · · ·
...
...
e1 e2
f1
g0

where
b1 =
a1a2 − a0a3
a1
b2 =
a1a4 − a0a5
a1
b3 =
a1a6 − a0a7
a1
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...
c1 =
b1a3 − a1b2
b1
c2 =
b1a5 − a1b3
b1
c3 =
b1a7 − a1b4
b1
...
d1 =
c1b2 − b1c2
c1
d2 =
c1b3 − b1c3
c1
...
The fixed point in question is stable if all the entries in the first column
of the Routh array are either all positive or all negative (Co, 1999).

Appendix B
Stability Analysis for the
Reduced System
This section completes the stability analysis of the fixed points (0, 0, 0, 0, 0, 0, A),
(0, 0, 0, 0, 0, H, A), (0, E6, 0, 0, 0, 0, 0), and (0, E6, 0, 0, 0, 0, A).
B.1 Stability of (0, 0, 0, 0, 0, 0, A) and (0, 0, 0, 0, 0, H, A)
The characteristic polynomial of Equation C.4 and Equation C.4 is
p(λ) = λ7 + a1λ6 + a2λ5 + a3λ4 + a4λ3 (B.1)
where
a1 = k2 + k5 + k7 + A*k10 + Eo*k1 + S*k3
a2 = k2*k5 + k2*k7 + k5*k7 + A*k2*k10 + A*k5*k10 + Eo*k1*k2 +
Eo*k1*k5 + Eo*k1*k7 + S*k2*k3 + A*Eo*k1*k10 + Eo*S*k1*k3
a3 = k2*k5*k7 + A*k2*k5*k10 + Eo*k1*k2*k5 + Eo*k1*k2*k7 +
Eo*k1*k5*k7 + A*Eo*k1*k2*k10 + A*Eo*k1*k5*k10 +
Eo*S*k1*k2*k3
a4 = Eo*k1*k2*k5*k7 + A*Eo*k1*k2*k5*k10 - Eo*S*k1*k2*k3*k5.
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The summary of the Routh Hurwitz Criteria gives the following require-
ments for stability of these two fixed points:
a1 > 0
a3 > 0
a4 > 0
a1a2a3 > a32 + a12a4.
Because the rate constants, Eo, and S are all positive values, we know that
a1 and a3 are positive. When we expand a1a2a3 > a32 + a12a4, not all the
terms are positive, so the stability of (0, 0, 0, 0, 0, 0, A) and (0, 0, 0, 0, 0, H, A)
is defined by
Eo*k1*k2*k5*k7 + A*Eo*k1*k2*k5*k10 - Eo*S*k1*k2*k3*k5 > 0
and
k1*k2*k3*k5*Eo*S(k3^2*S^2 - 2*k3*k5*S-k5^2) <
A*k10*(A*k10*(k2*k5*(k2 + k5)*(k2 + k5 + 3*k7) + Eo*k1*(Eo*k1
*(8*k2*k5 + 3*k2*k7 + 3*k5*k7 + 2*k2^2 + 2*k5^2 + Eo*k1*(k2 +
k5)) + k2^3 + 8*k2^2*k5 + 3*k7*k2^2 + 8*k2*k5^2 + 12*k7*k2*k5
+ k5^3 + 3*k7*k5^2)+ A*k10*(Eo*k1*(k2^2 + 4*k2*k5 + k5^2 +
Eo*k1*(k2 + k5))+ k2^2*k5)) + Eo*k1*(Eo*k1*(k2^3 + 8*k2^2*k5
+ 4*k2^2*k7 + 8*k2*k5^2 + 16*k2*k5*k7 + 3*k2*k7^2 + k5^3 +
4*k5^2*k7 + 3*k5*k7^2 + Eo*k1*(k2^2 + 4*k2*k5 +2*k7*k2 + k5^2
+ 2*k7*k5)) + (2*k2 + 2*k5 + 3*k7)*(2*k2^2*k5 + k7*k2^2 +
2*k2*k5^2 + 4*k7*k2*k5 + k7*k5^2))+ k2*k5*(k2 + k5)*(k2*k5 +
2*k2*k7 + 2*k5*k7 + 3*k7^2)) + Eo*k1*(Eo*k1*(Eo*k1*(k2^2*k5 +
k2^2*k7 + k2*k5^2 + 4*k2*k5*k7 + k2*k7^2 + k5^2*k7 + k5*k7^2)
+ (k2 + k5 + k7)*(k2^2*k5 + k2^2*k7 + k2*k5^2 + 6*k2*k5*k7 +
k2*k7^2 + k5^2*k7 + k5*k7^2)) + k2^3*k5^2 + 4*k2^3*k5*k7 +
k2^3*k7^2 + k2^2*k5^3 + 8*k2^2*k5^2*k7 + 8*k2^2*k5*k7^2 +
k2^2*k7^3 + 4*k2*k5^3*k7 + 8*k2*k5^2*k7^2 + 4*k2*k5*k7^3 +
k5^3*k7^2 + k5^2*k7^3)+k2*k5*k7*(k5 + k7)*(k2 + k7)*(k2 + k5)
+ S*k3*(A*k10*(Eo*k1*(Eo*k1*(9*k2*k5 + 6*k2*k7 + 4*k5*k7 +
4*k2^2 + 2*k5^2 + Eo*k1(2*k2+k5))+ 2*k2^3 + 9*k2^2*k5 +
6*k7*k2^2 + 6*k2*k5^2 + 14*k7*k2*k5 + 2*k7*k5^2)+k2^3*k5 +
2*k2^2*k5^2 + 2*k2*k5^2*k7 + 4*k2^2*k5*k7+ S*k3*(Eo*k1*(2*k2*k5
+ 3*k2^2 + Eo*k1*(3*k2+k5))+ 2*k5*k2^2)+ A*k10*(Eo*k1*(3*k2^2 +
7*k2*k5 + k5^2 + Eo*k1*(3*k2+2*k5))+ k2*k5*(2*k2 + k5)))+ S*k3
*(k2 + Eo*k1)*(Eo*k1*(k2*k5 + 3*k2*k7 + k5*k7 + k2^2 + Eo*k1*k2
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+ S*k2*k3)+ k2*k5*k7)+ Eo*k1*(Eo*k1*(Eo*k1*(k2*k5 + 2*k2*k7 +
k5*k7 + k2^2)+k2^3 + 2*k2^2*k5 + 4*k2^2*k7 + k2*k5^2 +
9*k2*k5*k7 + 3*k2*k7^2 + 2*k5^2*k7 + 2*k5*k7^2 ) + k2^3*k5 +
2*k2^3*k7 + k2^2*k5^2 + 9*k2^2*k5*k7 + 3*k2^2*k7^2 + 6*k2*k5^2*k7
+ 7*k2*k5*k7^2 + k5^2*k7^2)+ k2*k5*k7*(2*k2*k5 + 2*k2*k7 + k5*k7
+ k2^2)).
B.2 Stability of (0, E6, 0, 0, 0, 0, 0)
The characteristic polynomial of Equation C.7 is
p(λ) = λ7 + a1λ6 + a2λ5 + a3λ4 + a4λ3 + a5λ2 (B.2)
where
a1 = k2 + k5 + k7 + E6*k11 + Eo*k1 + S*k3
a2 = k2*k5 + k2*k7 + k5*k7 + E6*k2*k11 + E6*k5*k11 + E6*k7*k11
+ Eo*k1*k2 + Eo*k1*k5 + Eo*k1*k7 + S*k2*k3 + E6*Eo*k1*k11 +
E6*S*k3*k11 + Eo*S*k1*k3
a3 = k2*k5*k7 + E6*k2*k5*k11 + E6*k2*k7*k11 + E6*k5*k7*k11 +
Eo*k1*k2*k5 + Eo*k1*k2*k7 + Eo*k1*k5*k7 + E6*Eo*k1*k2*k11 +
E6*Eo*k1*k5*k11 + E6*Eo*k1*k7*k11 + E6*S*k2*k3*k11 +
Eo*S*k1*k2*k3 + E6*Eo*S*k1*k3*k11
a4 = E6*k2*k5*k7*k11 + Eo*k1*k2*k5*k7 + E6*Eo*k1*k2*k5*k11 +
E6*Eo*k1*k2*k7*k11 + E6*Eo*k1*k5*k7*k11 - Eo*S*k1*k2*k3*k5 +
E6*Eo*S*k1*k2*k3*k11
a5 = E6*Eo*k1*k2*k5*k7*k11 - E6*Eo*S*k1*k2*k3*k5*k11.
50 Stability Analysis for the Reduced System
The summary of the Routh Hurwitz Criteria gives the following require-
ments for stability of these two fixed points:
a1 > 0
a2 > 0
a3 > 0
a4 > 0
a5 > 0
a1a2a3 > a32 + a12a4
(a1a4 − a5)
(
a1a2a3 − a32 − a12a4
)
> a5(a1a2 − a3)2 + a1a52.
Because the rate constants, Eo, and S are all positive values, we know that
a1, a2, and a3 are positive. When we expand a1a2a3 > a32 + a12a4 and
(a1a4 − a5)
(
a1a2a3 − a32 − a12a4
)
> a5(a1a2 − a3)2 + a1a52, not all the terms
are positive, so the stability of (0, E6, 0, 0, 0, 0, 0) is defined by
E6*k2*k5*k7*k11 + E*k1*k2*k5*k7 + E6*E*k1*k2*k5*k11 +
E6*E*k1*k2*k7*k11 + E6*E*k1*k5*k7*k11 - E*S*k1*k2*k3*k5 +
E6*E*S*k1*k2*k3*k11 > 0,
E6*E*k1*k2*k5*k7*k11 - E6*E*S*k1*k2*k3*k5*k11 > 0,
(k2 + k5 + k7 + E6*k11 + Eo*k1 + S*k3)*(k2*k5 + k2*k7 + k5*k7 +
E6*k2*k11 + E6*k5*k11 + E6*k7*k11 + Eo*k1*k2 + Eo*k1*k5 +
Eo*k1*k7 + S*k2*k3 + E6*Eo*k1*k11 + E6*S*k3*k11 + Eo*S*k1*k3)
*(k2*k5*k7 + E6*k2*k5*k11 + E6*k2*k7*k11 + E6*k5*k7*k11 +
Eo*k1*k2*k5 + Eo*k1*k2*k7 + Eo*k1*k5*k7 + E6*Eo*k1*k2*k11 +
E6*Eo*k1*k5*k11 + E6*Eo*k1*k7*k11 + E6*S*k2*k3*k11 +
Eo*S*k1*k2*k3 + E6*Eo*S*k1*k3*k11) - (k2 + k5 + k7 + E6*k11 +
Eo*k1 + S*k3)^2*(E6*k2*k5*k7*k11 + Eo*k1*k2*k5*k7 +
E6*Eo*k1*k2*k5*k11 + E6*Eo*k1*k2*k7*k11 + E6*Eo*k1*k5*k7*k11
- Eo*S*k1*k2*k3*k5 + E6*Eo*S*k1*k2*k3*k11) - (k2*k5*k7 +
E6*k2*k5*k11 + E6*k2*k7*k11 + E6*k5*k7*k11 + Eo*k1*k2*k5 +
Eo*k1*k2*k7 + Eo*k1*k5*k7 + E6*Eo*k1*k2*k11 + E6*Eo*k1*k5*k11
+ E6*Eo*k1*k7*k11 + E6*S*k2*k3*k11 + Eo*S*k1*k2*k3 +
E6*Eo*S*k1*k3*k11)^2 > 0,
and
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- (E6*Eo*k1*k2*k5*k7*k11 - E6*Eo*S*k1*k2*k3*k5*k11)*(k2*k5*k7
- (k2 + k5 + k7 + E6*k11 + Eo*k1 + S*k3)*(k2*k5 + k2*k7 +
k5*k7 + E6*k2*k11 + E6*k5*k11 + E6*k7*k11 + Eo*k1*k2 +
Eo*k1*k5 + Eo*k1*k7 + S*k2*k3 + E6*Eo*k1*k11 + E6*S*k3*k11
+ Eo*S*k1*k3) + E6*k2*k5*k11 + E6*k2*k7*k11 + E6*k5*k7*k11
+ Eo*k1*k2*k5 + Eo*k1*k2*k7 + Eo*k1*k5*k7 + E6*Eo*k1*k2*k11
+ E6*Eo*k1*k5*k11 + E6*Eo*k1*k7*k11 + E6*S*k2*k3*k11 +
Eo*S*k1*k2*k3 + E6*Eo*S*k1*k3*k11)^2 -
(E6*Eo*k1*k2*k5*k7*k11 - E6*Eo*S*k1*k2*k3*k5*k11)^2*(k2 +
k5 + k7 + E6*k11 + Eo*k1 + S*k3) - ((k2 + k5 + k7 + E6*k11 +
Eo*k1 + S*k3)*(E6*k2*k5*k7*k11 + Eo*k1*k2*k5*k7 +
E6*Eo*k1*k2*k5*k11 + E6*Eo*k1*k2*k7*k11 + E6*Eo*k1*k5*k7*k11
- Eo*S*k1*k2*k3*k5 + E6*Eo*S*k1*k2*k3*k11)
- E6*Eo*k1*k2*k5*k7*k11 + E6*Eo*S*k1*k2*k3*k5*k11)*((k2*k5*k7
+ E6*k2*k5*k11 + E6*k2*k7*k11 + E6*k5*k7*k11 + Eo*k1*k2*k5 +
Eo*k1*k2*k7 + Eo*k1*k5*k7 + E6*Eo*k1*k2*k11 + E6*Eo*k1*k5*k11
+ E6*Eo*k1*k7*k11 + E6*S*k2*k3*k11 + Eo*S*k1*k2*k3 +
E6*Eo*S*k1*k3*k11)^2 + (k2 + k5 + k7 + E6*k11 + Eo*k1 +
S*k3)^2*(E6*k2*k5*k7*k11 + Eo*k1*k2*k5*k7 + E6*Eo*k1*k2*k5*k11
+ E6*Eo*k1*k2*k7*k11 + E6*Eo*k1*k5*k7*k11 - Eo*S*k1*k2*k3*k5 +
E6*Eo*S*k1*k2*k3*k11) - (k2 + k5 + k7 + E6*k11 + Eo*k1
+ S*k3)*(k2*k5 + k2*k7 + k5*k7 + E6*k2*k11 + E6*k5*k11 +
E6*k7*k11 + Eo*k1*k2 + Eo*k1*k5 + Eo*k1*k7 + S*k2*k3 +
E6*Eo*k1*k11 + E6*S*k3*k11 + Eo*S*k1*k3)*(k2*k5*k7 +
E6*k2*k5*k11 + E6*k2*k7*k11 + E6*k5*k7*k11 + Eo*k1*k2*k5 +
Eo*k1*k2*k7 + Eo*k1*k5*k7 + E6*Eo*k1*k2*k11 + E6*Eo*k1*k5*k11 +
E6*Eo*k1*k7*k11 + E6*S*k2*k3*k11 + Eo*S*k1*k2*k3 +
E6*Eo*S*k1*k3*k11)) > 0.
B.3 Stability of (0, E6, 0, 0, 0, 0, A)
The characteristic polynomial of Equation C.9 is
p(λ) = λ7 + a1λ6 + a2λ5 + a3λ4 + a4λ3 + a5λ2 (B.3)
where
a1 = k2 + k5 + k7 + A*k10 + E6*k11 + Eo*k1 + S*k3
a2 = k2*k5 + k2*k7 + k5*k7 + A*k2*k10 + A*k5*k10 + E6*k2*k11 +
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E6*k5*k11 + E6*k7*k11 + Eo*k1*k2 + Eo*k1*k5 + Eo*k1*k7 +
S*k2*k3 + A*E6*k10*k11 + A*Eo*k1*k10 + E6*Eo*k1*k11 +
E6*S*k3*k11 + Eo*S*k1*k3
a3 = k2*k5*k7 + A*k2*k5*k10 + E6*k2*k5*k11 + E6*k2*k7*k11 +
E6*k5*k7*k11 + Eo*k1*k2*k5 + Eo*k1*k2*k7 + Eo*k1*k5*k7 +
A*E6*k2*k10*k11 + A*E6*k5*k10*k11 + A*Eo*k1*k2*k10 +
A*Eo*k1*k5*k10 + E6*Eo*k1*k2*k11 + E6*Eo*k1*k5*k11 +
E6*Eo*k1*k7*k11 + E6*S*k2*k3*k11 + Eo*S*k1*k2*k3 +
A*E6*Eo*k1*k10*k11 + E6*Eo*S*k1*k3*k11
a4 = E6*k2*k5*k7*k11 + Eo*k1*k2*k5*k7 + A*E6*k2*k5*k10*k11 +
A*Eo*k1*k2*k5*k10 + E6*Eo*k1*k2*k5*k11 + E6*Eo*k1*k2*k7*k11
+ E6*Eo*k1*k5*k7*k11 - Eo*S*k1*k2*k3*k5 +
A*E6*Eo*k1*k2*k10*k11 + A*E6*Eo*k1*k5*k10*k11 +
E6*Eo*S*k1*k2*k3*k11
a5 = E6*Eo*k1*k2*k5*k7*k11 + A*E6*Eo*k1*k2*k5*k10*k11 -
E6*Eo*S*k1*k2*k3*k5*k11.
The summary of the Routh Hurwitz Criteria gives the following require-
ments for stability of these two fixed points:
a1 > 0
a2 > 0
a3 > 0
a4 > 0
a5 > 0
a1a2a3 > a32 + a12a4
(a1a4 − a5)
(
a1a2a3 − a32 − a12a4
)
> a5(a1a2 − a3)2 + a1a52.
Because the rate constants, Eo, and S are all positive values, we know that
a1, a2, and a3 are positive. When we expand a1a2a3 > a32 + a12a4 and
(a1a4 − a5)
(
a1a2a3 − a32 − a12a4
)
> a5(a1a2 − a3)2 + a1a52, not all the terms
are positive, so the stability of (0, E6, 0, 0, 0, 0, A) is defined by
E6*k2*k5*k7*k11 + Eo*k1*k2*k5*k7 + A*E6*k2*k5*k10*k11 +
A*Eo*k1*k2*k5*k10 + E6*Eo*k1*k2*k5*k11 + E6*Eo*k1*k2*k7*k11 +
E6*Eo*k1*k5*k7*k11 - Eo*S*k1*k2*k3*k5 + A*E6*Eo*k1*k2*k10*k11 +
A*E6*Eo*k1*k5*k10*k11 + E6*Eo*S*k1*k2*k3*k11 > 0,
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E6*Eo*k1*k2*k5*k7*k11 + A*E6*Eo*k1*k2*k5*k10*k11 -
E6*Eo*S*k1*k2*k3*k5*k11 > 0,
((k2 + k5 + k7 + E6*k11 + Eo*k1 + S*k3)*(k2*k5 + k2*k7 + k5*k7
+ E6*k2*k11 + E6*k5*k11 + E6*k7*k11 + Eo*k1*k2 + Eo*k1*k5 +
Eo*k1*k7 + S*k2*k3 + E6*Eo*k1*k11 + E6*S*k3*k11 +
Eo*S*k1*k3)*(k2*k5*k7 + E6*k2*k5*k11 + E6*k2*k7*k11 +
E6*k5*k7*k11 + Eo*k1*k2*k5 + Eo*k1*k2*k7 + Eo*k1*k5*k7 +
E6*Eo*k1*k2*k11 + E6*Eo*k1*k5*k11 + E6*Eo*k1*k7*k11 +
E6*S*k2*k3*k11 + Eo*S*k1*k2*k3 + E6*Eo*S*k1*k3*k11) - (k2 +
k5 + k7 + E6*k11 + Eo*k1 + S*k3)^2*(E6*k2*k5*k7*k11 +
Eo*k1*k2*k5*k7 + E6*Eo*k1*k2*k5*k11 + E6*Eo*k1*k2*k7*k11 +
E6*Eo*k1*k5*k7*k11 - Eo*S*k1*k2*k3*k5 + E6*Eo*S*k1*k2*k3*k11)
- (k2*k5*k7 + E6*k2*k5*k11 + E6*k2*k7*k11 + E6*k5*k7*k11 +
Eo*k1*k2*k5 + Eo*k1*k2*k7 + Eo*k1*k5*k7 + E6*Eo*k1*k2*k11 +
E6*Eo*k1*k5*k11 + E6*Eo*k1*k7*k11 + E6*S*k2*k3*k11 +
Eo*S*k1*k2*k3 + E6*Eo*S*k1*k3*k11)^2 > 0,
and
- (E6*Eo*k1*k2*k5*k7*k11 - E6*Eo*S*k1*k2*k3*k5*k11)*(k2*k5*k7
- (k2 + k5 + k7 + E6*k11 + Eo*k1 + S*k3)*(k2*k5 + k2*k7 + k5*k7
+ E6*k2*k11 + E6*k5*k11 + E6*k7*k11 + Eo*k1*k2 + Eo*k1*k5 +
Eo*k1*k7 + S*k2*k3 + E6*Eo*k1*k11 + E6*S*k3*k11 + Eo*S*k1*k3)
+ E6*k2*k5*k11 + E6*k2*k7*k11 + E6*k5*k7*k11 + Eo*k1*k2*k5 +
Eo*k1*k2*k7 + Eo*k1*k5*k7 + E6*Eo*k1*k2*k11 +
E6*Eo*k1*k5*k11 + E6*Eo*k1*k7*k11 + E6*S*k2*k3*k11 +
Eo*S*k1*k2*k3 + E6*Eo*S*k1*k3*k11)^2 - (E6*Eo*k1*k2*k5*k7*k11
- E6*Eo*S*k1*k2*k3*k5*k11)^2*(k2 + k5 + k7 + E6*k11 + Eo*k1 +
S*k3) - ((k2 + k5 + k7 + E6*k11 + Eo*k1 + S*k3)*(E6*k2*k5*k7*k11
+ Eo*k1*k2*k5*k7 + E6*Eo*k1*k2*k5*k11 + E6*Eo*k1*k2*k7*k11 +
E6*Eo*k1*k5*k7*k11 - Eo*S*k1*k2*k3*k5 + E6*Eo*S*k1*k2*k3*k11)
- E6*Eo*k1*k2*k5*k7*k11 + E6*Eo*S*k1*k2*k3*k5*k11)*((k2*k5*k7
+ E6*k2*k5*k11 + E6*k2*k7*k11 + E6*k5*k7*k11 + Eo*k1*k2*k5 +
Eo*k1*k2*k7 + Eo*k1*k5*k7 + E6*Eo*k1*k2*k11 + E6*Eo*k1*k5*k11
+ E6*Eo*k1*k7*k11 + E6*S*k2*k3*k11 + Eo*S*k1*k2*k3 +
E6*Eo*S*k1*k3*k11)^2 + (k2 + k5 + k7 + E6*k11 + Eo*k1 + S*k3)^2
*(E6*k2*k5*k7*k11 + Eo*k1*k2*k5*k7 + E6*Eo*k1*k2*k5*k11 +
E6*Eo*k1*k2*k7*k11 + E6*Eo*k1*k5*k7*k11 - Eo*S*k1*k2*k3*k5 +
E6*Eo*S*k1*k2*k3*k11) - (k2 + k5 + k7 + E6*k11 + Eo*k1 +
S*k3)*(k2*k5 + k2*k7 + k5*k7 + E6*k2*k11 + E6*k5*k11 + E6*k7*k11
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+ Eo*k1*k2 + Eo*k1*k5 + Eo*k1*k7 + S*k2*k3 + E6*Eo*k1*k11 +
E6*S*k3*k11 + Eo*S*k1*k3)*(k2*k5*k7 + E6*k2*k5*k11 +
E6*k2*k7*k11 + E6*k5*k7*k11 + Eo*k1*k2*k5 + Eo*k1*k2*k7 +
Eo*k1*k5*k7 + E6*Eo*k1*k2*k11 + E6*Eo*k1*k5*k11 +
E6*Eo*k1*k7*k11 + E6*S*k2*k3*k11 + Eo*S*k1*k2*k3 +
E6*Eo*S*k1*k3*k11)) > 0.
Appendix C
Stability Analysis for the Full
System
This section provides the reader with in depth criteria for the stability of the
fixed points of the full system.
C.1 Stability of (0, 0, 0, 0, 0, 0, 0, 0, 0) and (0, 0, 0, 0, 0, 0, 0, H, 0)
The Jacobian matrix at (0, 0, 0, 0, 0, 0, 0, 0, 0) is
J0 =

−k3S− k7 0 k2 0 0 k5 0 0 0
0 0 0 0 0 0 0 0 0
0 0 −k2 − k6 0 0 0 k1Eo 0 0
k7 0 k6 −k8 0 0 0 0 0
k3S 0 0 0 −k4 0 0 0 0
0 0 0 0 k4 −k5 0 0 0
0 0 0 0 0 k5 −k1Eo 0 0
0 0 0 0 0 0 k1Eo 0 0
0 0 0 0 0 0 0 0 0

,
(C.1)
and the Jacobian matrix at (0, 0, 0, 0, 0, 0, 0, H, 0) is
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JH =

−k3S− k7 0 k2 0 0 k5 0 0 0
0 0 0 0 0 0 0 0 0
0 0 −k2 − k6 0 0 0 k1Eo 0 0
k7 0 k6 −k8 0 0 0 0 0
k3S 0 0 0 −k4 0 0 0 0
0 0 0 0 k4 −k5 0 0 0
0 0 0 0 0 k5 −k1Eo 0 0
0 −k11H 0 0 0 0 k1Eo 0 0
0 0 0 0 0 0 0 0 0

.
(C.2)
These two fixed points share a characteristic polynomial, which is
p(λ) = λ9 + a1λ8 + a2λ7 + a3λ6 + a4λ5 + a5λ4 + a6λ3 (C.3)
where
a1 = k2 + k4 + k5 + k6 + k7 + k8 + Eo*k1 + S*k3
a2 = k2*k4 + k2*k5 + k2*k7 + k4*k5 + k2*k8 + k4*k6 + k4*k7 +
k5*k6 + k4*k8 + k5*k7 + k5*k8 + k6*k7 + k6*k8 + k7*k8 +
Eo*k1*k2 + Eo*k1*k4 + Eo*k1*k5 + Eo*k1*k6 + Eo*k1*k7 +
Eo*k1*k8 + S*k2*k3 + S*k3*k4 + S*k3*k5 + S*k3*k6 + S*k3*k8 +
Eo*S*k1*k3
a3 = k2*k4*k5 + k2*k4*k7 + k2*k4*k8 + k2*k5*k7 + k2*k5*k8 +
k4*k5*k6 + k4*k5*k7 + k2*k7*k8 + k4*k5*k8 + k4*k6*k7 + k4*k6*k8
+ k5*k6*k7 + k4*k7*k8 + k5*k6*k8 + k5*k7*k8 + k6*k7*k8 +
Eo*k1*k2*k4 + Eo*k1*k2*k5 + Eo*k1*k2*k7 + Eo*k1*k4*k5 +
Eo*k1*k2*k8 + Eo*k1*k4*k6 + Eo*k1*k4*k7 + Eo*k1*k5*k6 +
Eo*k1*k4*k8 + Eo*k1*k5*k7 + Eo*k1*k5*k8 + Eo*k1*k6*k7 +
Eo*k1*k6*k8 + Eo*k1*k7*k8 + S*k2*k3*k4 + S*k2*k3*k5 +
S*k2*k3*k8 + S*k3*k4*k6 + S*k3*k5*k6 + S*k3*k4*k8 + S*k3*k5*k8
+ S*k3*k6*k8 + Eo*S*k1*k2*k3 + Eo*S*k1*k3*k4 + Eo*S*k1*k3*k5
+ Eo*S*k1*k3*k6 + Eo*S*k1*k3*k8
a4 = k2*k4*k5*k7 + k2*k4*k5*k8 + k2*k4*k7*k8 + k2*k5*k7*k8 +
k4*k5*k6*k7 + k4*k5*k6*k8 + k4*k5*k7*k8 + k4*k6*k7*k8 +
k5*k6*k7*k8 + Eo*k1*k2*k4*k5 + Eo*k1*k2*k4*k7 + Eo*k1*k2*k4*k8
+ Eo*k1*k2*k5*k7 + Eo*k1*k2*k5*k8 + Eo*k1*k4*k5*k6 +
Stability of (0, 0, 0, 0, 0, 0, 0, 0, A) and (0, 0, 0, 0, 0, 0, 0, H, A) 57
Eo*k1*k4*k5*k7 + Eo*k1*k2*k7*k8 + Eo*k1*k4*k5*k8 +
Eo*k1*k4*k6*k7 + Eo*k1*k4*k6*k8 + Eo*k1*k5*k6*k7 +
Eo*k1*k4*k7*k8 + Eo*k1*k5*k6*k8 + Eo*k1*k5*k7*k8 +
Eo*k1*k6*k7*k8 + S*k2*k3*k4*k8 + S*k2*k3*k5*k8 + S*k3*k4*k6*k8
+ S*k3*k5*k6*k8 + Eo*S*k1*k2*k3*k4 + Eo*S*k1*k2*k3*k5 +
Eo*S*k1*k2*k3*k8 + Eo*S*k1*k3*k4*k6 + Eo*S*k1*k3*k5*k6 +
Eo*S*k1*k3*k4*k8 + Eo*S*k1*k3*k5*k8 + Eo*S*k1*k3*k6*k8
a5 = k2*k4*k5*k7*k8 + k4*k5*k6*k7*k8 + Eo*k1*k2*k4*k5*k7 +
Eo*k1*k2*k4*k5*k8 + Eo*k1*k2*k4*k7*k8 + Eo*k1*k2*k5*k7*k8 +
Eo*k1*k4*k5*k6*k7 + Eo*k1*k4*k5*k6*k8 + Eo*k1*k4*k5*k7*k8 +
Eo*k1*k4*k6*k7*k8 + Eo*k1*k5*k6*k7*k8 - Eo*S*k1*k2*k3*k4*k5 +
Eo*S*k1*k2*k3*k4*k8 + Eo*S*k1*k2*k3*k5*k8 +
Eo*S*k1*k3*k4*k6*k8 + Eo*S*k1*k3*k5*k6*k8
a6 = Eo*k1*k2*k4*k5*k7*k8 + Eo*k1*k4*k5*k6*k7*k8 -
Eo*S*k1*k2*k3*k4*k5*k8
C.2 Stability of (0, 0, 0, 0, 0, 0, 0, 0, A) and (0, 0, 0, 0, 0, 0, 0, H, A)
The stabilities of these fixed points are functions of A. The Jacobian matrix
at (0, 0, 0, 0, 0, 0, 0, 0, A) is
JA =

−k3S− k7 − k10 A 0 k2 0 0 k5 0 0 0
0 0 0 0 0 0 0 0 0
0 0 −k2 − k6 0 0 0 k1Eo 0 0
k7 0 k6 −k8 0 0 0 0 0
k3S 0 0 0 −k4 0 0 0 0
0 0 0 0 k4 −k5 0 0 0
0 0 0 0 0 k5 −k1Eo 0 0
0 0 0 0 0 0 k1Eo 0 0
−k10A 0 0 0 0 0 0 0 0

,
(C.4)
and the Jacobian matrix at (0, 0, 0, 0, 0, 0, 0, H, A) is
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JH,A =

−k3S− k7 − k10A 0 k2 0 0 k5 0 0 0
0 0 0 0 0 0 0 0 0
0 0 −k2 − k6 0 0 0 k1Eo 0 0
k7 0 k6 −k8 0 0 0 0 0
k3S 0 0 0 −k4 0 0 0 0
0 0 0 0 k4 −k5 0 0 0
0 0 0 0 0 k5 −k1Eo 0 0
0 −k11H 0 0 0 0 k1Eo 0 0
−k10A 0 0 0 0 0 0 0 0

.
(C.5)
These two fixed points share a characteristic polynomial, which is
p(λ) = λ9 + a1λ8 + a2λ7 + a3λ6 + a4λ5 + a5λ4 + a6λ3 (C.6)
where
a1 = k2 + k4 + k5 + k6 + k7 + k8 + A*k10 + Eo*k1 + S*k3
a2 = k2*k4 + k2*k5 + k2*k7 + k4*k5 + k2*k8 + k4*k6 + k4*k7 +
k5*k6 + k4*k8 + k5*k7 + k5*k8 + k6*k7 + k6*k8 + k7*k8 + A*k2*k10
+ A*k4*k10 + A*k5*k10 + A*k6*k10 + A*k8*k10 + Eo*k1*k2 +
Eo*k1*k4 + Eo*k1*k5 + Eo*k1*k6 + Eo*k1*k7 + Eo*k1*k8 + S*k2*k3
+ S*k3*k4 + S*k3*k5 + S*k3*k6 + S*k3*k8 + A*Eo*k1*k10 +
Eo*S*k1*k3
a3 = k2*k4*k5 + k2*k4*k7 + k2*k4*k8 + k2*k5*k7 + k2*k5*k8 +
k4*k5*k6 + k4*k5*k7 + k2*k7*k8 + k4*k5*k8 + k4*k6*k7 +
k4*k6*k8 + k5*k6*k7 + k4*k7*k8 + k5*k6*k8 + k5*k7*k8 + k6*k7*k8
+ A*k2*k4*k10 + A*k2*k5*k10 + A*k4*k5*k10 + A*k2*k8*k10 +
A*k4*k6*k10 + A*k5*k6*k10 + A*k4*k8*k10 + A*k5*k8*k10 +
A*k6*k8*k10 + Eo*k1*k2*k4 + Eo*k1*k2*k5 + Eo*k1*k2*k7 +
Eo*k1*k4*k5 + Eo*k1*k2*k8 + Eo*k1*k4*k6 + Eo*k1*k4*k7 +
Eo*k1*k5*k6 + Eo*k1*k4*k8 + Eo*k1*k5*k7 + Eo*k1*k5*k8 +
Eo*k1*k6*k7 + Eo*k1*k6*k8 + Eo*k1*k7*k8 + S*k2*k3*k4 +
S*k2*k3*k5 + S*k2*k3*k8 + S*k3*k4*k6 + S*k3*k5*k6 + S*k3*k4*k8 +
S*k3*k5*k8 + S*k3*k6*k8 + A*Eo*k1*k2*k10 + A*Eo*k1*k4*k10 +
A*Eo*k1*k5*k10 + A*Eo*k1*k6*k10 + A*Eo*k1*k8*k10 +
Eo*S*k1*k2*k3 + Eo*S*k1*k3*k4 + Eo*S*k1*k3*k5 + Eo*S*k1*k3*k6
+ Eo*S*k1*k3*k8
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a4 = k2*k4*k5*k7 + k2*k4*k5*k8 + k2*k4*k7*k8 + k2*k5*k7*k8 +
k4*k5*k6*k7 + k4*k5*k6*k8 + k4*k5*k7*k8 + k4*k6*k7*k8 +
k5*k6*k7*k8 + A*k2*k4*k5*k10 + A*k2*k4*k8*k10 + A*k2*k5*k8*k10
+ A*k4*k5*k6*k10 + A*k4*k5*k8*k10 + A*k4*k6*k8*k10 +
A*k5*k6*k8*k10 + Eo*k1*k2*k4*k5 + Eo*k1*k2*k4*k7 +
Eo*k1*k2*k4*k8 + Eo*k1*k2*k5*k7 + Eo*k1*k2*k5*k8 +
Eo*k1*k4*k5*k6 + Eo*k1*k4*k5*k7 + Eo*k1*k2*k7*k8 +
Eo*k1*k4*k5*k8 + Eo*k1*k4*k6*k7 + Eo*k1*k4*k6*k8 +
Eo*k1*k5*k6*k7 + Eo*k1*k4*k7*k8 + Eo*k1*k5*k6*k8 +
Eo*k1*k5*k7*k8 + Eo*k1*k6*k7*k8 + S*k2*k3*k4*k8 + S*k2*k3*k5*k8
+ S*k3*k4*k6*k8 + S*k3*k5*k6*k8 + A*Eo*k1*k2*k4*k10 +
A*Eo*k1*k2*k5*k10 + A*Eo*k1*k4*k5*k10 + A*Eo*k1*k2*k8*k10 +
A*Eo*k1*k4*k6*k10 + A*Eo*k1*k5*k6*k10 + A*Eo*k1*k4*k8*k10 +
A*Eo*k1*k5*k8*k10 + A*Eo*k1*k6*k8*k10 + Eo*S*k1*k2*k3*k4 +
Eo*S*k1*k2*k3*k5 + Eo*S*k1*k2*k3*k8 + Eo*S*k1*k3*k4*k6 +
Eo*S*k1*k3*k5*k6 + Eo*S*k1*k3*k4*k8 + Eo*S*k1*k3*k5*k8 +
Eo*S*k1*k3*k6*k8
a5 = k2*k4*k5*k7*k8 + k4*k5*k6*k7*k8 + A*k2*k4*k5*k8*k10 +
A*k4*k5*k6*k8*k10 + Eo*k1*k2*k4*k5*k7 + Eo*k1*k2*k4*k5*k8 +
Eo*k1*k2*k4*k7*k8 + Eo*k1*k2*k5*k7*k8 + Eo*k1*k4*k5*k6*k7 +
Eo*k1*k4*k5*k6*k8 + Eo*k1*k4*k5*k7*k8 + Eo*k1*k4*k6*k7*k8 +
Eo*k1*k5*k6*k7*k8 - Eo*S*k1*k2*k3*k4*k5 + Eo*S*k1*k2*k3*k4*k8 +
Eo*S*k1*k2*k3*k5*k8 + Eo*S*k1*k3*k4*k6*k8 + Eo*S*k1*k3*k5*k6*k8
+ A*Eo*k1*k2*k4*k5*k10 + A*Eo*k1*k2*k4*k8*k10 +
A*Eo*k1*k2*k5*k8*k10 + A*Eo*k1*k4*k5*k6*k10 +
A*Eo*k1*k4*k5*k8*k10 + A*Eo*k1*k4*k6*k8*k10 +
A*Eo*k1*k5*k6*k8*k10
a6 = Eo*k1*k2*k4*k5*k7*k8 + Eo*k1*k4*k5*k6*k7*k8 +
A*Eo*k1*k2*k4*k5*k8*k10 + A*Eo*k1*k4*k5*k6*k8*k10 -
Eo*S*k1*k2*k3*k4*k5*k8
C.3 Stability of (0, E6, 0, 0, 0, 0, 0, 0, 0)
The stability of this fixed point is a function of E6. The Jacobian matrix at
(0, E6, 0, 0, 0, 0, 0, 0, 0) is
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JE6 =

−k3S− k7 0 k2 0 0 k5 0 0 0
0 0 0 0 0 0 0 0 0
0 0 −k2 − k6 0 0 0 k1Eo 0 0
k7 0 k6 −k8 0 0 0 0 0
k3S 0 0 0 −k4 0 0 0 0
0 0 0 0 k4 −k5 0 0 0
0 0 0 0 0 k5 −k1Eo 0 0
0 0 0 0 0 0 k1Eo −k11E6 0
0 0 0 0 0 0 0 0 0

.
(C.7)
The characteristic polynomial for this fixed point is
p(λ) = λ9 + a1λ8 + a2λ7 + a3λ6 + a4λ5 + a5λ4 + a6λ3 + a7λ2 (C.8)
where
a1 = k2 + k4 + k5 + k6 + k7 + k8 + E6*k11 + Eo*k1 + S*k3
a2 = k2*k4 + k2*k5 + k2*k7 + k4*k5 + k2*k8 + k4*k6 + k4*k7 +
k5*k6 + k4*k8 + k5*k7 + k5*k8 + k6*k7 + k6*k8 + k7*k8 +
E6*k2*k11 + E6*k4*k11 + E6*k5*k11 + E6*k6*k11 + E6*k7*k11 +
E6*k8*k11 + Eo*k1*k2 + Eo*k1*k4 + Eo*k1*k5 + Eo*k1*k6 +
Eo*k1*k7 + Eo*k1*k8 + S*k2*k3 + S*k3*k4 + S*k3*k5 + S*k3*k6
+ S*k3*k8 + E6*Eo*k1*k11 + E6*S*k3*k11 + Eo*S*k1*k3
a3 = k2*k4*k5 + k2*k4*k7 + k2*k4*k8 + k2*k5*k7 + k2*k5*k8 +
k4*k5*k6 + k4*k5*k7 + k2*k7*k8 + k4*k5*k8 + k4*k6*k7 +
k4*k6*k8 + k5*k6*k7 + k4*k7*k8 + k5*k6*k8 + k5*k7*k8 +
k6*k7*k8 + E6*k2*k4*k11 + E6*k2*k5*k11 + E6*k2*k7*k11 +
E6*k4*k5*k11 + E6*k2*k8*k11 + E6*k4*k6*k11 + E6*k4*k7*k11 +
E6*k5*k6*k11 + E6*k4*k8*k11 + E6*k5*k7*k11 + E6*k5*k8*k11 +
E6*k6*k7*k11 + E6*k6*k8*k11 + E6*k7*k8*k11 + Eo*k1*k2*k4 +
Eo*k1*k2*k5 + Eo*k1*k2*k7 + Eo*k1*k4*k5 + Eo*k1*k2*k8 +
Eo*k1*k4*k6 + Eo*k1*k4*k7 + Eo*k1*k5*k6 + Eo*k1*k4*k8 +
Eo*k1*k5*k7 + Eo*k1*k5*k8 + Eo*k1*k6*k7 + Eo*k1*k6*k8 +
Eo*k1*k7*k8 + S*k2*k3*k4 + S*k2*k3*k5 + S*k2*k3*k8 +
S*k3*k4*k6 + S*k3*k5*k6 + S*k3*k4*k8 + S*k3*k5*k8 +
S*k3*k6*k8 + E6*Eo*k1*k2*k11 + E6*Eo*k1*k4*k11 +
E6*Eo*k1*k5*k11 + E6*Eo*k1*k6*k11 + E6*Eo*k1*k7*k11 +
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E6*Eo*k1*k8*k11 + E6*S*k2*k3*k11 + E6*S*k3*k4*k11 +
E6*S*k3*k5*k11 + E6*S*k3*k6*k11 + E6*S*k3*k8*k11 +
Eo*S*k1*k2*k3 + Eo*S*k1*k3*k4 + Eo*S*k1*k3*k5 +
Eo*S*k1*k3*k6 + Eo*S*k1*k3*k8 + E6*Eo*S*k1*k3*k11
a4 = k2*k4*k5*k7 + k2*k4*k5*k8 + k2*k4*k7*k8 + k2*k5*k7*k8 +
k4*k5*k6*k7 + k4*k5*k6*k8 + k4*k5*k7*k8 + k4*k6*k7*k8 +
k5*k6*k7*k8 + E6*k2*k4*k5*k11 + E6*k2*k4*k7*k11 +
E6*k2*k4*k8*k11 + E6*k2*k5*k7*k11 + E6*k2*k5*k8*k11 +
E6*k4*k5*k6*k11 + E6*k4*k5*k7*k11 + E6*k2*k7*k8*k11 +
E6*k4*k5*k8*k11 + E6*k4*k6*k7*k11 + E6*k4*k6*k8*k11 +
E6*k5*k6*k7*k11 + E6*k4*k7*k8*k11 + E6*k5*k6*k8*k11 +
E6*k5*k7*k8*k11 + E6*k6*k7*k8*k11 + Eo*k1*k2*k4*k5 +
Eo*k1*k2*k4*k7 + Eo*k1*k2*k4*k8 + Eo*k1*k2*k5*k7 +
Eo*k1*k2*k5*k8 + Eo*k1*k4*k5*k6 + Eo*k1*k4*k5*k7 +
Eo*k1*k2*k7*k8 + Eo*k1*k4*k5*k8 + Eo*k1*k4*k6*k7 +
Eo*k1*k4*k6*k8 + Eo*k1*k5*k6*k7 + Eo*k1*k4*k7*k8 +
Eo*k1*k5*k6*k8 + Eo*k1*k5*k7*k8 + Eo*k1*k6*k7*k8 +
S*k2*k3*k4*k8 + S*k2*k3*k5*k8 + S*k3*k4*k6*k8 + S*k3*k5*k6*k8
+ E6*Eo*k1*k2*k4*k11 + E6*Eo*k1*k2*k5*k11 +
E6*Eo*k1*k2*k7*k11 + E6*Eo*k1*k4*k5*k11 + E6*Eo*k1*k2*k8*k11
+ E6*Eo*k1*k4*k6*k11 + E6*Eo*k1*k4*k7*k11 +
E6*Eo*k1*k5*k6*k11 + E6*Eo*k1*k4*k8*k11 + E6*Eo*k1*k5*k7*k11
+ E6*Eo*k1*k5*k8*k11 + E6*Eo*k1*k6*k7*k11 + E6*Eo*k1*k6*k8*k11
+ E6*Eo*k1*k7*k8*k11 + E6*S*k2*k3*k4*k11 + E6*S*k2*k3*k5*k11 +
E6*S*k2*k3*k8*k11 + E6*S*k3*k4*k6*k11 + E6*S*k3*k5*k6*k11 +
E6*S*k3*k4*k8*k11 + E6*S*k3*k5*k8*k11 + E6*S*k3*k6*k8*k11 +
Eo*S*k1*k2*k3*k4 + Eo*S*k1*k2*k3*k5 + Eo*S*k1*k2*k3*k8 +
Eo*S*k1*k3*k4*k6 + Eo*S*k1*k3*k5*k6 + Eo*S*k1*k3*k4*k8 +
Eo*S*k1*k3*k5*k8 + Eo*S*k1*k3*k6*k8 + E6*Eo*S*k1*k2*k3*k11 +
E6*Eo*S*k1*k3*k4*k11 + E6*Eo*S*k1*k3*k5*k11 +
E6*Eo*S*k1*k3*k6*k11 + E6*Eo*S*k1*k3*k8*k11
a5 = k2*k4*k5*k7*k8 + k4*k5*k6*k7*k8 + E6*k2*k4*k5*k7*k11 +
E6*k2*k4*k5*k8*k11 + E6*k2*k4*k7*k8*k11 + E6*k2*k5*k7*k8*k11 +
E6*k4*k5*k6*k7*k11 + E6*k4*k5*k6*k8*k11 + E6*k4*k5*k7*k8*k11 +
E6*k4*k6*k7*k8*k11 + E6*k5*k6*k7*k8*k11 + Eo*k1*k2*k4*k5*k7 +
Eo*k1*k2*k4*k5*k8 + Eo*k1*k2*k4*k7*k8 + Eo*k1*k2*k5*k7*k8 +
Eo*k1*k4*k5*k6*k7 + Eo*k1*k4*k5*k6*k8 + Eo*k1*k4*k5*k7*k8 +
Eo*k1*k4*k6*k7*k8 + Eo*k1*k5*k6*k7*k8 + E6*Eo*k1*k2*k4*k5*k11 +
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E6*Eo*k1*k2*k4*k7*k11 + E6*Eo*k1*k2*k4*k8*k11 +
E6*Eo*k1*k2*k5*k7*k11 + E6*Eo*k1*k2*k5*k8*k11 +
E6*Eo*k1*k4*k5*k6*k11 + E6*Eo*k1*k4*k5*k7*k11 +
E6*Eo*k1*k2*k7*k8*k11 + E6*Eo*k1*k4*k5*k8*k11 +
E6*Eo*k1*k4*k6*k7*k11 + E6*Eo*k1*k4*k6*k8*k11 +
E6*Eo*k1*k5*k6*k7*k11 + E6*Eo*k1*k4*k7*k8*k11 +
E6*Eo*k1*k5*k6*k8*k11 + E6*Eo*k1*k5*k7*k8*k11 +
E6*Eo*k1*k6*k7*k8*k11 + E6*S*k2*k3*k4*k8*k11 +
E6*S*k2*k3*k5*k8*k11 + E6*S*k3*k4*k6*k8*k11 +
E6*S*k3*k5*k6*k8*k11 - Eo*S*k1*k2*k3*k4*k5 +
Eo*S*k1*k2*k3*k4*k8 + Eo*S*k1*k2*k3*k5*k8 + Eo*S*k1*k3*k4*k6*k8
+ Eo*S*k1*k3*k5*k6*k8 + E6*Eo*S*k1*k2*k3*k4*k11 +
E6*Eo*S*k1*k2*k3*k5*k11 + E6*Eo*S*k1*k2*k3*k8*k11 +
E6*Eo*S*k1*k3*k4*k6*k11 + E6*Eo*S*k1*k3*k5*k6*k11 +
E6*Eo*S*k1*k3*k4*k8*k11 + E6*Eo*S*k1*k3*k5*k8*k11 +
E6*Eo*S*k1*k3*k6*k8*k11
a6 = E6*k2*k4*k5*k7*k8*k11 + E6*k4*k5*k6*k7*k8*k11 +
Eo*k1*k2*k4*k5*k7*k8 + Eo*k1*k4*k5*k6*k7*k8 +
E6*Eo*k1*k2*k4*k5*k7*k11 + E6*Eo*k1*k2*k4*k5*k8*k11 +
E6*Eo*k1*k2*k4*k7*k8*k11 + E6*Eo*k1*k2*k5*k7*k8*k11 +
E6*Eo*k1*k4*k5*k6*k7*k11 + E6*Eo*k1*k4*k5*k6*k8*k11 +
E6*Eo*k1*k4*k5*k7*k8*k11 + E6*Eo*k1*k4*k6*k7*k8*k11 +
E6*Eo*k1*k5*k6*k7*k8*k11 - Eo*S*k1*k2*k3*k4*k5*k8 -
E6*Eo*S*k1*k2*k3*k4*k5*k11 + E6*Eo*S*k1*k2*k3*k4*k8*k11 +
E6*Eo*S*k1*k2*k3*k5*k8*k11 + E6*Eo*S*k1*k3*k4*k6*k8*k11 +
E6*Eo*S*k1*k3*k5*k6*k8*k11
a7 = E6*Eo*k1*k2*k4*k5*k7*k8*k11 +
E6*Eo*k1*k4*k5*k6*k7*k8*k11 - E6*Eo*S*k1*k2*k3*k4*k5*k8*k11
C.4 Stability of (0, E6, 0, 0, 0, 0, 0, 0, A)
The stability of this fixed point is a function of E6 and A. The Jacobian
matrix at (0, E6, 0, 0, 0, 0, 0, 0, A) is
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JE6,A =

−k3S− k7 − k10A 0 k2 0 0 k5 0 0 0
0 0 0 0 0 0 0 0 0
0 0 −k2 − k6 0 0 0 k1Eo 0 0
k7 0 k6 −k8 0 0 0 0 0
k3S 0 0 0 −k4 0 0 0 0
0 0 0 0 k4 −k5 0 0 0
0 0 0 0 0 k5 −k1Eo 0 0
0 0 0 0 0 0 k1Eo −k11E6 0
−k10 A 0 0 0 0 0 0 0 0

.
(C.9)
The characteristic polynomial for this fixed point is
p(λ) = λ9 + a1λ8 + a2λ7 + a3λ6 + a4λ5 + a5λ4 + a6λ3 + a7λ2 (C.10)
where
a1 = k2 + k4 + k5 + k6 + k7 + k8 + A*k10 + E6*k11 + Eo*k1 +
S*k3
a2 = k2*k4 + k2*k5 + k2*k7 + k4*k5 + k2*k8 + k4*k6 + k4*k7 +
k5*k6 + k4*k8 + k5*k7 + k5*k8 + k6*k7 + k6*k8 + k7*k8 +
A*k2*k10 + A*k4*k10 + A*k5*k10 + A*k6*k10 + A*k8*k10 +
E6*k2*k11 + E6*k4*k11 + E6*k5*k11 + E6*k6*k11 + E6*k7*k11
+ E6*k8*k11 + Eo*k1*k2 + Eo*k1*k4 + Eo*k1*k5 + Eo*k1*k6 +
Eo*k1*k7 + Eo*k1*k8 + S*k2*k3 + S*k3*k4 + S*k3*k5 + S*k3*k6
+ S*k3*k8 + A*E6*k10*k11 + A*Eo*k1*k10 + E6*Eo*k1*k11 +
E6*S*k3*k11 + Eo*S*k1*k3
a3 = k2*k4*k5 + k2*k4*k7 + k2*k4*k8 + k2*k5*k7 + k2*k5*k8 +
k4*k5*k6 + k4*k5*k7 + k2*k7*k8 + k4*k5*k8 + k4*k6*k7 +
k4*k6*k8 + k5*k6*k7 + k4*k7*k8 + k5*k6*k8 + k5*k7*k8 +
k6*k7*k8 + A*k2*k4*k10 + A*k2*k5*k10 + A*k4*k5*k10 +
A*k2*k8*k10 + A*k4*k6*k10 + A*k5*k6*k10 + A*k4*k8*k10 +
A*k5*k8*k10 + A*k6*k8*k10 + E6*k2*k4*k11 + E6*k2*k5*k11 +
E6*k2*k7*k11 + E6*k4*k5*k11 + E6*k2*k8*k11 + E6*k4*k6*k11
+ E6*k4*k7*k11 + E6*k5*k6*k11 + E6*k4*k8*k11 + E6*k5*k7*k11
+ E6*k5*k8*k11 + E6*k6*k7*k11 + E6*k6*k8*k11 + E6*k7*k8*k11
+ Eo*k1*k2*k4 + Eo*k1*k2*k5 + Eo*k1*k2*k7 + Eo*k1*k4*k5 +
Eo*k1*k2*k8 + Eo*k1*k4*k6 + Eo*k1*k4*k7 + Eo*k1*k5*k6 +
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Eo*k1*k4*k8 + Eo*k1*k5*k7 + Eo*k1*k5*k8 + Eo*k1*k6*k7 +
Eo*k1*k6*k8 + Eo*k1*k7*k8 + S*k2*k3*k4 + S*k2*k3*k5 +
S*k2*k3*k8 + S*k3*k4*k6 + S*k3*k5*k6 + S*k3*k4*k8 + S*k3*k5*k8
+ S*k3*k6*k8 + A*E6*k2*k10*k11 + A*E6*k4*k10*k11 +
A*E6*k5*k10*k11 + A*E6*k6*k10*k11 + A*E6*k8*k10*k11 +
A*Eo*k1*k2*k10 + A*Eo*k1*k4*k10 + A*Eo*k1*k5*k10 +
A*Eo*k1*k6*k10 + A*Eo*k1*k8*k10 + E6*Eo*k1*k2*k11 +
E6*Eo*k1*k4*k11 + E6*Eo*k1*k5*k11 + E6*Eo*k1*k6*k11 +
E6*Eo*k1*k7*k11 + E6*Eo*k1*k8*k11 + E6*S*k2*k3*k11 +
E6*S*k3*k4*k11 + E6*S*k3*k5*k11 + E6*S*k3*k6*k11 +
E6*S*k3*k8*k11 + Eo*S*k1*k2*k3 + Eo*S*k1*k3*k4 +
Eo*S*k1*k3*k5 + Eo*S*k1*k3*k6 + Eo*S*k1*k3*k8 +
A*E6*Eo*k1*k10*k11 + E6*Eo*S*k1*k3*k11
a4 = k2*k4*k5*k7 + k2*k4*k5*k8 + k2*k4*k7*k8 + k2*k5*k7*k8 +
k4*k5*k6*k7 + k4*k5*k6*k8 + k4*k5*k7*k8 + k4*k6*k7*k8 +
k5*k6*k7*k8 + A*k2*k4*k5*k10 + A*k2*k4*k8*k10 + A*k2*k5*k8*k10
+ A*k4*k5*k6*k10 + A*k4*k5*k8*k10 + A*k4*k6*k8*k10 +
A*k5*k6*k8*k10 + E6*k2*k4*k5*k11 + E6*k2*k4*k7*k11 +
E6*k2*k4*k8*k11 + E6*k2*k5*k7*k11 + E6*k2*k5*k8*k11 +
E6*k4*k5*k6*k11 + E6*k4*k5*k7*k11 + E6*k2*k7*k8*k11 +
E6*k4*k5*k8*k11 + E6*k4*k6*k7*k11 + E6*k4*k6*k8*k11 +
E6*k5*k6*k7*k11 + E6*k4*k7*k8*k11 + E6*k5*k6*k8*k11 +
E6*k5*k7*k8*k11 + E6*k6*k7*k8*k11 + Eo*k1*k2*k4*k5 +
Eo*k1*k2*k4*k7 + Eo*k1*k2*k4*k8 + Eo*k1*k2*k5*k7 +
Eo*k1*k2*k5*k8 + Eo*k1*k4*k5*k6 + Eo*k1*k4*k5*k7 +
Eo*k1*k2*k7*k8 + Eo*k1*k4*k5*k8 + Eo*k1*k4*k6*k7 +
Eo*k1*k4*k6*k8 + Eo*k1*k5*k6*k7 + Eo*k1*k4*k7*k8 +
Eo*k1*k5*k6*k8 + Eo*k1*k5*k7*k8 + Eo*k1*k6*k7*k8 +
S*k2*k3*k4*k8 + S*k2*k3*k5*k8 + S*k3*k4*k6*k8 + S*k3*k5*k6*k8 +
A*E6*k2*k4*k10*k11 + A*E6*k2*k5*k10*k11 + A*E6*k4*k5*k10*k11
+ A*E6*k2*k8*k10*k11 + A*E6*k4*k6*k10*k11 + A*E6*k5*k6*k10*k11
+ A*E6*k4*k8*k10*k11 + A*E6*k5*k8*k10*k11 + A*E6*k6*k8*k10*k11
+ A*Eo*k1*k2*k4*k10 + A*Eo*k1*k2*k5*k10 + A*Eo*k1*k4*k5*k10 +
A*Eo*k1*k2*k8*k10 + A*Eo*k1*k4*k6*k10 + A*Eo*k1*k5*k6*k10 +
A*Eo*k1*k4*k8*k10 + A*Eo*k1*k5*k8*k10 + A*Eo*k1*k6*k8*k10 +
E6*Eo*k1*k2*k4*k11 + E6*Eo*k1*k2*k5*k11 + E6*Eo*k1*k2*k7*k11 +
E6*Eo*k1*k4*k5*k11 + E6*Eo*k1*k2*k8*k11 + E6*Eo*k1*k4*k6*k11 +
E6*Eo*k1*k4*k7*k11 + E6*Eo*k1*k5*k6*k11 + E6*Eo*k1*k4*k8*k11 +
E6*Eo*k1*k5*k7*k11 + E6*Eo*k1*k5*k8*k11 + E6*Eo*k1*k6*k7*k11 +
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E6*Eo*k1*k6*k8*k11 + E6*Eo*k1*k7*k8*k11 + E6*S*k2*k3*k4*k11 +
E6*S*k2*k3*k5*k11 + E6*S*k2*k3*k8*k11 + E6*S*k3*k4*k6*k11 +
E6*S*k3*k5*k6*k11 + E6*S*k3*k4*k8*k11 + E6*S*k3*k5*k8*k11 +
E6*S*k3*k6*k8*k11 + Eo*S*k1*k2*k3*k4 + Eo*S*k1*k2*k3*k5 +
Eo*S*k1*k2*k3*k8 + Eo*S*k1*k3*k4*k6 + Eo*S*k1*k3*k5*k6 +
Eo*S*k1*k3*k4*k8 + Eo*S*k1*k3*k5*k8 + Eo*S*k1*k3*k6*k8 +
A*E6*Eo*k1*k2*k10*k11 + A*E6*Eo*k1*k4*k10*k11
+ A*E6*Eo*k1*k5*k10*k11 + A*E6*Eo*k1*k6*k10*k11 +
A*E6*Eo*k1*k8*k10*k11 + E6*Eo*S*k1*k2*k3*k11 +
E6*Eo*S*k1*k3*k4*k11 + E6*Eo*S*k1*k3*k5*k11 +
E6*Eo*S*k1*k3*k6*k11 + E6*Eo*S*k1*k3*k8*k11
a5 = k2*k4*k5*k7*k8 + k4*k5*k6*k7*k8 + A*k2*k4*k5*k8*k10 +
A*k4*k5*k6*k8*k10 + E6*k2*k4*k5*k7*k11 + E6*k2*k4*k5*k8*k11 +
E6*k2*k4*k7*k8*k11 + E6*k2*k5*k7*k8*k11 + E6*k4*k5*k6*k7*k11 +
E6*k4*k5*k6*k8*k11 + E6*k4*k5*k7*k8*k11 + E6*k4*k6*k7*k8*k11 +
E6*k5*k6*k7*k8*k11 + Eo*k1*k2*k4*k5*k7 + Eo*k1*k2*k4*k5*k8 +
Eo*k1*k2*k4*k7*k8 + Eo*k1*k2*k5*k7*k8 + Eo*k1*k4*k5*k6*k7 +
Eo*k1*k4*k5*k6*k8 + Eo*k1*k4*k5*k7*k8 + Eo*k1*k4*k6*k7*k8 +
Eo*k1*k5*k6*k7*k8 + E6*Eo*k1*k2*k4*k5*k11 +
E6*Eo*k1*k2*k4*k7*k11 + E6*Eo*k1*k2*k4*k8*k11 +
E6*Eo*k1*k2*k5*k7*k11 + E6*Eo*k1*k2*k5*k8*k11 +
E6*Eo*k1*k4*k5*k6*k11 + E6*Eo*k1*k4*k5*k7*k11 +
E6*Eo*k1*k2*k7*k8*k11 + E6*Eo*k1*k4*k5*k8*k11 +
E6*Eo*k1*k4*k6*k7*k11 + E6*Eo*k1*k4*k6*k8*k11 +
E6*Eo*k1*k5*k6*k7*k11 + E6*Eo*k1*k4*k7*k8*k11 +
E6*Eo*k1*k5*k6*k8*k11 + E6*Eo*k1*k5*k7*k8*k11 +
E6*Eo*k1*k6*k7*k8*k11 + E6*S*k2*k3*k4*k8*k11 +
E6*S*k2*k3*k5*k8*k11 + E6*S*k3*k4*k6*k8*k11 +
E6*S*k3*k5*k6*k8*k11 - Eo*S*k1*k2*k3*k4*k5 +
Eo*S*k1*k2*k3*k4*k8 + Eo*S*k1*k2*k3*k5*k8 +
Eo*S*k1*k3*k4*k6*k8 + Eo*S*k1*k3*k5*k6*k8 +
A*E6*k2*k4*k5*k10*k11 + A*E6*k2*k4*k8*k10*k11 +
A*E6*k2*k5*k8*k10*k11 + A*E6*k4*k5*k6*k10*k11 +
A*E6*k4*k5*k8*k10*k11 + A*E6*k4*k6*k8*k10*k11 +
A*E6*k5*k6*k8*k10*k11 + A*Eo*k1*k2*k4*k5*k10 +
A*Eo*k1*k2*k4*k8*k10 + A*Eo*k1*k2*k5*k8*k10
+ A*Eo*k1*k4*k5*k6*k10 + A*Eo*k1*k4*k5*k8*k10
+ A*Eo*k1*k4*k6*k8*k10 + A*Eo*k1*k5*k6*k8*k10 +
A*E6*Eo*k1*k2*k4*k10*k11 + A*E6*Eo*k1*k2*k5*k10*k11 +
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A*E6*Eo*k1*k4*k5*k10*k11 + A*E6*Eo*k1*k2*k8*k10*k11 +
A*E6*Eo*k1*k4*k6*k10*k11 + A*E6*Eo*k1*k5*k6*k10*k11 +
A*E6*Eo*k1*k4*k8*k10*k11 + A*E6*Eo*k1*k5*k8*k10*k11 +
A*E6*Eo*k1*k6*k8*k10*k11 + E6*Eo*S*k1*k2*k3*k4*k11 +
E6*Eo*S*k1*k2*k3*k5*k11 + E6*Eo*S*k1*k2*k3*k8*k11 +
E6*Eo*S*k1*k3*k4*k6*k11 + E6*Eo*S*k1*k3*k5*k6*k11 +
E6*Eo*S*k1*k3*k4*k8*k11 + E6*Eo*S*k1*k3*k5*k8*k11 +
E6*Eo*S*k1*k3*k6*k8*k11
a6 = E6*k2*k4*k5*k7*k8*k11 + E6*k4*k5*k6*k7*k8*k11 +
Eo*k1*k2*k4*k5*k7*k8 + Eo*k1*k4*k5*k6*k7*k8 +
A*E6*k2*k4*k5*k8*k10*k11 + A*E6*k4*k5*k6*k8*k10*k11
+ A*Eo*k1*k2*k4*k5*k8*k10 + A*Eo*k1*k4*k5*k6*k8*k10 +
E6*Eo*k1*k2*k4*k5*k7*k11 + E6*Eo*k1*k2*k4*k5*k8*k11 +
E6*Eo*k1*k2*k4*k7*k8*k11 + E6*Eo*k1*k2*k5*k7*k8*k11 +
E6*Eo*k1*k4*k5*k6*k7*k11 + E6*Eo*k1*k4*k5*k6*k8*k11 +
E6*Eo*k1*k4*k5*k7*k8*k11 + E6*Eo*k1*k4*k6*k7*k8*k11 +
E6*Eo*k1*k5*k6*k7*k8*k11 - Eo*S*k1*k2*k3*k4*k5*k8 +
A*E6*Eo*k1*k2*k4*k5*k10*k11 + A*E6*Eo*k1*k2*k4*k8*k10*k11 +
A*E6*Eo*k1*k2*k5*k8*k10*k11 + A*E6*Eo*k1*k4*k5*k6*k10*k11 +
A*E6*Eo*k1*k4*k5*k8*k10*k11 + A*E6*Eo*k1*k4*k6*k8*k10*k11 +
A*E6*Eo*k1*k5*k6*k8*k10*k11 - E6*Eo*S*k1*k2*k3*k4*k5*k11 +
E6*Eo*S*k1*k2*k3*k4*k8*k11 + E6*Eo*S*k1*k2*k3*k5*k8*k11 +
E6*Eo*S*k1*k3*k4*k6*k8*k11 + E6*Eo*S*k1*k3*k5*k6*k8*k11
a7 = E6*Eo*k1*k2*k4*k5*k7*k8*k11 + E6*Eo*k1*k4*k5*k6*k7*k8*k11
+ A*E6*Eo*k1*k2*k4*k5*k8*k10*k11 +
A*E6*Eo*k1*k4*k5*k6*k8*k10*k11 - E6*Eo*S*k1*k2*k3*k4*k5*k8*k11
C.5 Applying the Routh-Hurwitz Criterion
The fixed points (0, 0, 0, 0, 0, 0, 0, 0, 0), (0, 0, 0, 0, 0, 0, 0, H, 0),
(0, 0, 0, 0, 0, 0, 0, 0, A), and (0, 0, 0, 0, 0, 0, 0, H, A) result in a Routh array for
n = 6.
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The Routh array for the above fixed points is
J =

a6 a4 a2 0
a5 a3 a1 0
A B 0 0
C D 0 0
E 0 0 0
D 0 0 0
D 0 0 0

(C.11)
where
A =
a5a4 − a3a6
a5
B =
a3a2 − a1a4
a5
C = a3 − a5 (a3a2 − a1a4)a5a4 − a3a6
D =
a1 (a3a2 − a1a4)
a5a4 − a3a6
E =
a3 (a1a4 − a2a3) (a1a6 − a2a5 − a3a6 + a4a5)
a32a6 − a1a4a5 + a2a3a5 − a3a4a5 ,
and we want a6, a5, A, C, E, and D to all be either positive or negative.
The fixed points (0, E6, 0, 0, 0, 0, 0, 0, 0) and (0, E6, 0, 0, 0, 0, 0, 0, A) result
in a Routh array for n = 7:
J =

a7 a5 a3 a1 0
a6 a4 a2 0 0
A B C 0 0
D E 0 0 0
F G 0 0 0
H 0 0 0 0
G 0 0 0 0
G 0 0 0 0

(C.12)
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where
A =
a6a5 − a4a7
a6
B =
a4a3 − a2a5
a6
C =
a1a2
a6
D = a4 − a6 (a3a4 − a2a5)a5a6 − a4a7
E =
a2 (a1a4 + a2a5 − a3a4)
a4a7 − a5a6
F =
a4 (a2 (a7 (a2a5 − a3a4 − a4a5 + a1a4)− a5a6 (a1 + a3 − a5)) + a3a4 (a3a6 + a4a7 − a5a6))
a6 (a4 (a4a7 + a3a6)− a5a6 (a2 + a4))
G =
−a1a22 (a1a4 + a2a5 − a3a4)
(a4a7 − a5a6)2
H =
EF− DG
F
and we want a7, a6, A, D, F, H, and G to all be either positive or negative.
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